REGISTERED CHARITY NUMBER: 1159115
Report of the 'fru$tees and
inancial StAtements for the Year Ended 31 ivlareh 2024
for
British PaediAlric Tr4eurology Association

Brltlsh Paedlatrlc Neurology Assoclatlon
Contents of the Flnancial Ststements
for the Year Ended 31 March 2024
Page
Report of the Trustees
I to 29
Report of the Independen¢ Audltor
30 10 32
Statement of Financial Actlvities
33 to 34
Balance Sheet
35
Cash Flow Statement
36
Notes to the CAsh Flow Slatement
37
Notes to the Financlal Statements
38 to 60

British Paediatric Neurology Association
Report ol the Trustees
Cor the Year Ended 31 March 2024
The Iruslees present Iheir report with the financial statements of the charity for the year ended 31 March 2024. The trustees
have adoplc(I thc provisions of Acc'ounting and Rcporting by Charities= Statement of Recommended Practice applicable io
charities preparing their accounts in accordance with the Financial Reporting Stsndard applicable in the UK and Repiiblic of
Iicland (FRS 102) (cffcclivc l January 2019).
Pre5ident'5 Report
It has bcen a pleasuic lo take over tlie Presidcncy of the BPNA with the organisation in such great shape. I would like to
6(ari by thanking Alasdair Paikcr. immediutc Past President, for his strong leadership navigating Lhe BPNA out of the
pandemic and strengthening our work acro.ss all our charitable activities. The BPNA h&s now reached Ihe status of a
mediiim charity on aCCOUDI of our financial iuTnoYcr and with growing outputs across all areas of the organisation.
Particular highlights in 2023-24-
UK Education continues to grow and refresh. PET4ward h&8 been develoFd as a new Course and there have been uwiales
io existing courses lo ensure these remain slate of the arl. There was a return of some courses lo F￿e io Face whilsi
coniinuing Some in the virtual environmenl in order lo meet the needs of the parlicipanls.
Iniernational Education 15 moving forwards with establishing courses in new countries incliiding a launch in Zambia for
ZambAalZAmbabwe and continuing to work with Ilie International League Against Epilepsy (ILAE) to facilitate the roll-out
of PEf worldwide. The International team were successful in attaining a competitive Tropi¢al Health and Education Trust
(THET) grant 10 Support the BPNA to work with partners in Ghana and Kenya to roll PETI out in rural areas.
Patient and Public Involvement collalx)ralion has broadened beyond input lo conference and includes feedback to infom
short course development, meeting with patient groups and linking in with SExcial Interest Groups
A very successful 50th annual conference in Bristol from scientific, networking and social perspectives with 726 delegates
from 47 countries
A growing membership with over 700 members
Conunuing io attract trainees to Paediatric Neurology and overseeing the training of Ihe next generation of Paediatric
Neurologists and supporting the training of other medical professionals
Appoinlment of Philip L£vine as Dittcior and expansion of the secretariat to deliver the increasing activities of the
organisation
Over Ihc ncxt ycar wc plan to consolidate and further develop. The 8lrategy day in Septemkr 2024 will be opporlunily lo
onsidcr the vision of the BPNA and how we can achieve ihi% t()geiher.
would really like 10 thank thc Sccrclariat, Exccutive, Council, all BPNA members and volunteers for their continuing
ccjmmilmenl and cnihusiabm for thc activilics of thc organisation.
The day job. in Ihc NHS is IKcoming increasingly challenging and despite this you find time to work together to deliver our
haritable aim of promoting the health and well-being of children with neurological disorders.
Dr Ailsa McLellan
BPNA President (2024 - 2027)
Page I

Bri¢tsh Paediatric Neurology Association
Report of the Trustees
for the Year Ended 31 Mareh 2024
OBJEcfivES AND ACTIVITIES
Objectlves and aims
The British Paediatric Neurology Association (BPNA) is a charitable incorporated organisalion registered wilh ihe Charity
Commission for England and Wales on 6 November 2014 with the charity number 1159115.
The objectives are co proniote the health and well-being of children with neurological disorders through:
The training and edu¢ation of professionals working in the field of paediatric neurosciences-
The promotion of ￿Search into the causes, effects and trearmenis of neurological disorders affecltng children and
young people,.
The improvement of knowledge of professionals, the publi¢ and patients and their families Ihrough scientific and
educational meelings., and
The provision of professional support to members io facilitaie the delivery of the above objectives and work with
t]ealth servA¢e planners and providers lo achieve this aim.
Main activities undertaken in relation to the purpose
Please see full details of each activity provided in 'Achievement and performance,.
Training the next generation of paediatric neurologisis in the UK.
Educating professiona18 in the UK and internationally in ihe diagnosis and manageTnenl of..
Epilepsy, through provision of Paediatric Epilepsy Training (PET) and Expert to Expert-
Epilepsy courses,.
Movement disorders, through provision of Expert to Expert.. Movement Disorders;
Headaches, through provision of Children's Headache Training (CHaT) courses.,
Neonatal neurology, through provision of INeoNATE) ¢ourses
Abnormal muscle lone, through provision of the Approaching Children's Tone (ACT) COLirses
Acute neurological disorders through ihe newly developed course Acute
Children with any type of neiirological condition through its comprehensive online distance
learning course.
Improvemenl of knowledge of professionals, the public and paiients through the annual scientific meeting held in
JanLiary.
Promotion of research through..
British Paediatric Neurology Surveillance Unli (BPNSU)., and
Paediatric Neurology Research Fellowship.
Provision of professional support through:
Mentoring;
Team support.,
Special interest groups
Page 2

British Paediatric Neurology Assoclatlon
Report of the Trnstees
for the Year Ended 31 March 2024
Public benefit
The Iruslees have had regard lo the Charity Commission's guidance on public benefit in considering activilies during
2023-24. They sought lo meet the public benefit of promoting the health and wellbeing of children with neurological
disorders in the UK and globally through the initiative5 and projecis listed in the section 'Main activities undertaken in
relation to the purpose,.
OBJECTIVKS AND ACTIVITIES
GrAntm8king
During 2023-24, th¢ Charity provided £41,302 funding the third year for the second joint BPNA A¢lion Medical Research
{AMR) fellowship and £41,667 funding the second year for the third joint BPNA Aclion Medical Research fellowship.
Volunteers
BPNA faculty in the UK and overseas directly contributed to the development and delivery of courses and distance learning.
They also contribute their expertise in the other areas of the BPNA including Professional Support and Research as Chair,
Council and Committee members. YoLi can define all these people as volunteers who give their time to the BPNA as a
charity. Their contribution is significant to the ongoing activates of the BPNA and the trustees wholeheartedly appreciate
this commitment and thank them.
Fundralslng
BPNA raises funds through applying for grants from organisaiions Ihal have the same interests.
The charity has used its own staff for fundraising and not any external fundraiser.%.
Tlie cliarily is not a member of any voluntary scheme for regulating fundraising.
All fundraising activitie5 are monilored by the Direclor and the charity has not received any complaints regarding its
fundraising activities.
The charity doesn't come into contact with vulnerable people as it is not involved with street or door to door fundraising.
ACHIEVEMENT AND PERFORMANCE
Charitable •etivities
l. Tralning
l. l. P<iediatric Neurolo
Siib-s
ecialt Traiiiiiio
The BPNA Continues lo have responsibility for training paedialric neurologists in the UK with BPNA members serving on
the Royal College of Paediatrics and Child Health (RCPCH) College Specialist Advisory Committee ICSAC) for
neurology.The committee is Chaired by the BPNA President and include8 the BPNA National Training Advisor.
The GMC and RCPCH Shape of Training (SOT) plans on paediairi¢ neurology training are now finalised and will be
comTnencing in August 2023. Il has been agreed that neurology GRID trainees will still have up lo 3.5 years lo meet
learning d)jeclives.
.2. New curriculum
Trainees and their ediicational supervisors are becoming more familiar with the Level 3 neurology 'Progress' syllabus,
which was launched in August 2018. The BPNA Training Guide to Neurology, published on the RCPCH website, continues
io provide more specific and structured information on how to achieve the learning objectives and capabilities for Level 3
neurology (GRLD) training. The CSAC has developed an Annual Progression Form which incorporates the curriculum and
trainees have provided positive feedback regarding this.
.3.A
oinlineiii ()f new
rid Ir4Trinee.
For the 2023 paedialric neurology GRID Iraining programme, there were 9 GRID training schemes available. Over thirty
applications were received, and 19 trainee5 were shortlisted for interview. 16 candidates were deemed appointable, and 9
trainees accepted a GRID position. Overall, this is a hLige increase in number of trainees applying to the GRID scheme in
comparison lo previous years.
Page 3

British Paediatri¢ Neurology Association
Report of the Trustees
lor the Year Ended 31 March 202A
There has also been a change in number of attempts ai GRID applications. Unlimiied aitempts are now being allowed.
provided the trainee has had equivalenl training up to the siage of entry, counting a m&ximum of 12 months of equivalettt
experience.
In 2020. the BPNA established a Recruitmenl Working Group lo develop strategieb to encourage junior do¢tors lo consider
a career in paediatrtc iieurology. Variou5 initiatives have been implemented to aid prospective irainees in making successful
applications inclLiding a careers page on ihe BPNA web8i¢e with webinars on applica(ions and interviews and genei'al iopics
in paedtairic neurology. Feedback on Ihese sessions have been very posiiive overall.
1.4. As'%es%iiienl und SLI
orl for Existin Trainee
All traii)ees receive an annual viriual CSAC progression interview. In the past year, mosi trainees have been making good
progress. There are challenges for some irainees to access outpatient aciivities in specific centres and the Neurology CSAC
have been supporting the local ieams to address ihis. A shortage of consultants in substantive posts has impacied on their
ability lo irain in some cenires.
1.5.S
ecial Inicrcsl
niocllilc in E ill
The Neurology CSAC have rewrillen ihc Special Inieresl (SPIN) Epilepsy curriculum in 2022 and this has now been
endorsed and signed off by the RCPCH. The BPNA are l(K)king al more ways to support Trainees taking on SPIN Epilepsy.
1.6. Ai4eE¥ffleIii of'Noii-Grid' Trainin
Doctors who have noi completed the UK paediatric neurology GRID training prograwnme. bul who can show they have
knowledge. skills and experience equivalenl to the approved curriculum. can request entry on the GMC specialty register
via the ceri1fica￿ of Eligibility for Specialist Registration (CESRI route, if part of their (raining was done overseas. The
Neurology CSAC has a role in evaluaiing CESR applieations. If the GMC approve the initial appliealion. the Neurology
CSAC will review the neurology component of their training and determine wheiher il is equivalent to that of a UK GRID
Irainee. Typically, only training in ihe 5 years prior to the CESR applicaiion can be?considered and if successful, Ihe
applicant will eniered onto the GMC speclalist register.
If a irainee cannot apply for CESR accredilaiion, they can apply lo the CSAC to delermine whether iheir training has been
'eqiiivalent' to Ihat of a UK GRtD trainee. Given the difficulty in assessing training via the generic NHS shortlisling
programme and lor dui'ing a brief inierview, this is a more robust method of supporiing the RCPCH represeniative on
Advisory Appoinlmenls Commiltees (AAC) in ensuring that candidates applying for a consiiltant paediatric neurology post
are suilably irained to fulfil the role. Of note. a 'Leller of Equivalence, does not allow entry on the specialist register.
1.7. A
rnvul ol New Posi%
Job plans for all new consulianl paediatric neurologisl posis submitied by hospitals lo the RCPCH for approval are reviewed
by Ihe Neurology CSAC. The Generic Guide lo Consultant Paediairic Neurologist Job Planning, published by the BPNA
in 2018, has been invaluable in supporting centres in ensuring their jobs are sustainable and will allow new consulianis lo
meet the needs of children and young people with neurological disorders. Final approval for consultant paediatric
neurology jobs is given by the RCPCH Training Serviee.g team.
2. Education
210 BPNA taculty in the UK and overseas directly contribuied to the developmeni and delivery of coiirses during 2023-24.
This demonstrates the strong motivation and engagement of faculty, and ihe trLisiees wholeheai'iedly appreciate this
commitment to teaching and Iraining.
The BPNA short courses run either in a virtual or face-lo-fa¢e setting. wilh the majority taking place online. Sonie courses
are hoping io return back to a face-lo-face setting or a mixlure of running the courses both online and face-lo-face and some
remaining eniirely online.
Page 4

Brltish Paediatric Neurology Assoclatlon
Repor¢ of the Trustees
for the Year Ended 31 March 2024
l. Pdcdiatric Epilcpsy Triiiniii
PET
PET Icaches safe slandard epilepsy praclice to clinicians, using conscnsus-based. peer-reviewed. standardised materials
linked lo inlernalionally rcco¥ni5cd clinical guidelines. Introduced to improve sthndards of care ol childrcn with cpilcpsy,
we aim lo d¢liv¢r courscb thioughout the UK every year.
AII PETI, PET2 and PET3 courses took place in a virtual .qetting again in ycar 2023-24 with PET week {PET123 in one
wcek) running in a face-to-face seLling. Virlual ¢ourscs have tEsulted in a reduced number of PET courses compared io
when they ran face-to-face pre-pandcmiL'.
PETI (l-day) 6 courses (2019-20=10)
PE12 (2-d&ys) 3 courscs (2019-20J- )
- PET3 (2-days) 2 courses {2019-204)
Since 2005 to 31 March 2024, 12,840 UK clinicians have allended a PET course (2023-24=697. 2022-23=726-
2021-2L702). contributing to improving the standards of diagnosis and management of children with epilepsy in the UK.
Feedback from virtual ¢our5es has been excellelll.
The PETI course materials were updated by a team of internalional clinicians in March 2023. The updated PETI materials
were used in the UK froTll May 2023. The PET23 course materials were updatrd by a team of international clinicians in
November 2023. The updated PET23 materials will be used in (he UK from June 2024. A Consulianl Paediatrician with a
special interesl in epilepsy is employed for 4-hours per week to manage course development.
Q 2. Cliildrcn's 14eaduche Traiiiiii
CHa'r
This one-day course is delivered by paediatric neurologists and paediatricians with expertise in the management of
headaclie. The purpose of CHaT is to improve knowledge and skills amongsl health professionals who care for children and
young people with headache.
CHaT was adapted for virtual delivery during the coronavirus pandemic. In 2023-24, four virtual CHaT courses were held.
During 2023-24 CHaT welcomed internalional attendees from Austria, Belgium, Greece, malt￿ New Zealand, Norway,
Sudan, Turkey and United Arab Emirates.
CHaT course materials were updated by a UK fram in 2018.
Since 2012, 1.661 clinicians have attended CHaT {2023-2AL163. 2022-23=198. 2021-22-138. 2020-21-117).
2.3. NLonalal Nclirolo
As%e%smenl llnd Ti'eatnieni Bdlicaiioii
NeoNAI'E
Infanl8 born at Icrm vr prcmalurely are susceptible to neurological condilions whose long-lenn OLilcomc6 Can bc much
improved by cffcclivc carly rccognition and intervention. "I'his prnclical 2-day cour5c was inlroduccd in 2014 to provide
training for paedidiriLian6 dnd nconatologibts caring for newborn infants in dislricl general ho8pilal8. It 18 delivered by
paediatric neurolo¥isls and nconatologisL5, lind this unique course gives a complemenlary per8￿Ctive on a wide range ol
ncurological conditions.
NeoNATB course nialerials were updaied by a UK team in 2018.
The NeoNATE course was not adaptcd for virtual dclivery and no courses run during the pandemic, belween 2020 - 2022.
In 2023-24, NeDNAI'E ran two courscs hcld in a facc-lo-face setting. Since 2014. 708 clinicians have attended NeoNATE
(2023-24=72. 2022-23=80", 2021-224); 2020-21=0). During 2023-24 NeoNATE welcomed international attendees from
RomaniL Singapore and Switzerland.
Page 5

British Paediatric Neurology Association
Report of the Trustees
for the Year Ended 31 March 2024
2.4. E,x
erl to bx
erl
InleTnational keynote speakers and UK faculiy deliver an annual 2-day course, providing coniinuing professional
development for Consuliani Paediatric Neurologists from the UK and globally. On alternate years, the course focuses on
Epilepsy or Movement Disorders.
In 2022-23. 39 people allended Expert to Expert: Epilepsy, wilh international attendees from Malaysia I l ), Netherlands12}
and Norway (l }. The next course will rake place in 2024-25.
CliildF¢n's Tone
ACT
Children with abnormal muscle lone deserve prompl recognilioii and timely access lo appropriate invesligalion and
treatment, parlicularly with the availabilily of new therapies foi. neLiromuscular conditions and cerebral palsy. In view of
Lhis. the BPNA developed a short course on tone managemeni in children called 'Approa¢hing Children's Tone, (ACT).
The Acr ¢ours¢ was developed for virlual delivery. Since the running of the first course in 2020-21. 350 clinicians have
a[￿llded ACT (2023-24=128; 2022-23=94. 2021-22=92; 2020-21=36).
2.6 AcLlte Paediairic NLurolo
Il is estimated that aboui a third of all paediatric emergencies are neurological. We are aware of Ihe volume of children
attending emergency departments with neiirological preseniaiions, and of ihe anxiety this can create for the re¢eiving
paediatricians and trainees, who often feel inadequately trained in acuie paedialric neurology. In view of this. the BPNA in
collaboration with the Association of Paedialric Emergency Medicine developed a l-day course called Acute Paediairic
Neurology.
The Acute course was developed for virlual delivery. Sin¢e Ihe running of the firs( course in 2021-22. 199 clinicians have
aiiended Acute (2023-24-73; 2022-23=91: 2021-22=35).
2.7 Mnveiiieni Disorder% EIlLICiilion
MOVED
Unusual movements in children Can sometimes be difficult lo describe and ¢ategorise. MOVED is a 2-day course which aims
lo cover a broad spectrum of movement disorders thal are seen in children and will place emphasis on description, diagnosis
and initial management of these conditions. Thi5 newly developed course has been adapted from the previous Expert to
Expert: Movement Disorders course.
The MOVED course was developed foi both vlriual and face-lo-face delivery. The first course ran in 2023-24 with 35
linicians aiiending.
2.8. 1)ISl<lliCC LLariJin
In¢roduction
Distance Learning (DL) provides sysrematic and comprehensive learningi delivered online for trainee paediatric
neurologists, paedialricians and established specialists. The course covers the whole of paediatric neurology and
palli¢ipants may enrol for one or more unils. DL fees are differentiated by couniry according lo (he World Bank eeonomic
classificalion lo widen access lo doctors worldwide, in line with BPNA charitable aims. During 2023-24, 181 doctors
eni'olled from 35 countries.
in PaLdiali'ic Neurolo Tr
Distance L£arning complements BPNA short courses. providing depth and exlending the knowledge gained at a one- and
(wo-day courses. Woi'king with respective short-course development teams. explicit links are being provided in DL units
to reinforce ihe learning provided in the related short-courses. Thus, we en¢ourage'.
PET attendees to study Unit 6 Epilepsy
NeoNATE attendees lo sludy Unil 2 Neonalal Neurology
CHaT allendee5 to study Unil 12 Headache
ACT aiiendees to study Unit 5 Neuromuscular and Unit 4 Ceniral Motor Disorders
A¢uie Paediatric Neurology attendees lo study Unil 13 Acute Paedialric Neurology
Page 6

British PaediatTie Neurology Association
Report of the Truslees
for the Year Ended 31 MArch 2024
Updating content
Dislance Learning is hosted on the Moodle plarforn).
A Consultant Pucdialri¢ Neurologist is employed for 4-hours per week to direct and oversee the constanl revision and
rewriting pmcess. The Dislance Lvatning Sl¢cring Group. consisting of onel two experts per unit, meets twice per year.
Distance Learning development hab u reserve lo fuTJd dcvclopmenl for upjaling Units and paying for the external Moodle
plailoim piovidcr cfilus Lcatning)2021-2024. During 2023-24, Unli 8 Inflammation and infection of the CNS major U￿tale
was complctcd.
Enrolments
During 2023-24, there have been 503 cniolments on distance learning units. by 181 people from 35 counlries. The highcsl
proportion of Lhese cnrolments are from the UK, 50.79% (256 of 503).
Of Éhose 503 enrolments 135 of those were as part of a bundle package.
Acknowledgements
We are indebied to the Consultant Paediatric Neurologist volunteer liiiors in the UK and globally, who give their time to
lulor students ihrough the course. We give enorn)oiis thanks to &11 those Consultants across the subspecialties who
ontribute to the course contenl development, including preparing and givffing BPNA webinars.
2.9. Webinar Leciure Series
Covid-19 led io a ¢l)ang¢ in trainee'5 working patterns ihat resulted in them having restricied access to appropriate leaching.
In response, the BPNA Presideni launched a free weekly Webinar Lecture Series.
BPNA webinar leciure serie5 wa5 launched as a free weekly viriual learning resource for child health professionals, in
parti¢ul&i' those working in paediats'ic neurosciences worldwide.
The first lecture was given on 14 May 2020 and lectures have been delivered weekly up until September 2022, with a
couple of short breaks for holidays. Since October 2022 the webinar lectures have been delivered on a monihly basis with
focus on special interest condition topics that the BPNA Special Interest Group Chairs suggests. This would not have been
possible withoiit the generosity of BPNA members giving their lime. We are graleful (o Ihem all for preparing and
delivering such excellent IcLlures on wide range of topics and for remaining until all the question5 have been answered.
Recordings of IcL'lures a￿ available in the BPNA members, area and are also provided on the distance learning platform for
enrolled students to access.
During 2023-24, the webinar Icctiire series has been attended by boih IrainLCS and consulianis worldwide. 776 doctors and
allied health prufcs.4iUll¢i16 from 64 countries have atlended 9 BPNA monthly wcbinar Iccturcs.
11 ha5 been acknowledged that the webinars are a grLUt promotion to thc BPNA'S brand and charitable objectives and ihal
Ihcy should carry on.
2.10. Inlernalional ShDrt-Courses
In 2022. the World 14ealth As5cmbly unanimously ratified ihe WHO'S In(er8ectoral Gl(Jbal Action Plan OD epilcpsy and
other neurological disorders. PET contributes to strengthening Ihe health workforce. one OF the Plan's key levers for change.
Ag&in.st this backdrop, we were pleased io see internauon&l PET atlendco numbers rising to pre-pandemic levels in 2023-24,
as well as the launch of PETI in Zambia and Zimbabwe. We are grateful to the ILAE and Ihe BAND Foundation for their
support of the launch. We were also pleased to secure a grani from ihe Tropical Health and Education Trusl (THET),
awarded on behalf of the Department of Health and Social Care. The grant was awarded under THET'S Global Health
Workforce Programme and 15 supporting the BPNA to work with partners in Ghana and Kenya lo roll PETI out in rural
areas.
Page 7

Britlsh Paediatric Neurology Association
Report of the Trnstees
for the Year Ended 31 March 2024
Thig was the second year of BPNA'S new four-year partnership (2022-2026) with the International League Against Epilepsy
(ILAE), whivh was fonned to lacilitalc the roll-oui of PET worldwide. The initial memoranduTll of underqlanding has a
value of $278,844 ovcr that time. Trustccs are cogniNdnt vl. thc need to ensiire international launch and delivery of courses
is SLlStainable and that all Course.￿ meet our dcftned qualily standurds.
The BPNA and ILAF. sharc a commitmenl lo iJnproving care foi children wilh epilcp5y. In 2005, the BPNA developed
Pl￿[IatrIC Epilepsy 'fraining (PET) courses lo train hcalthcare workers to bcttei diagnose and trcat children wilh 5cizures.
PETI is now atlendcd by almost every pacdiatrician in Ihe UK und the course.q have also bccn launched ovcr5cas, 8eiiing a
gold siandard tor epilepqy cai'c around the world. Oulsidc of the UK. the programme currenily runs in.. Aiistralia, Brazil.
Colombia, Ghana, Lndia, Kcnya. New Z¢aland, Singapore. South Alrica, Tanzania. Uganda, Zambia and Zimbabwe.
PET aligns with the ILAE'S Educ<ltion Council'5 aim to leach compelency in the diagnosis and clinical management of
epilepsy, wirh a focus on non-specialists i.e. paedialricTans. It forms parl of the porEfolio of educationdl aclivilies thai the
ILAE aims to develop. It also supports Goal 2 of the ILAE'5 Strategy 2030- Support health professionals worldwide to
enhance their knowledge and skills in the prevention. diagnosis, Ireatment and care of epilepsy.
The BPNA and the ILAE first signed a partnership agreement in 2018, committing to build on the success of the Paedialric
Epilepsy Training courses developed by (he BPNA.
The ILAE hab ag￿ed to cover 40% of staff costs in ihe BPNA'S International Education team (3 staff members) from April
2022 to March 2026.
The total number of attendees outside the UK and Republic of Ireland is 6,825 (PETI = 5,327. PET2 = 624; PET3 = 283;
iPET= 274; Trained as faculiy = 285).
2.10. l. Middll E¢i%l & Nordi Al riLu
Middle East.. No courses were delivered in 2023-24.
PF.Tl altendance sinc¥ 2014.. 171 (2023-24= O- 2022-23 = 0. 2021-22 = 15).
PET2 atlendance since 2014.. 133 (2023-24= 0; 2022-23 - 0. 2021-22 = 14).
North Africa..
SuLlan= No Sudanesc altendeeq joincd at PET or PF.T2 course in 2022-23. Due to the gco-political situaiion, courses in
Suddll have been paused.
PETI allcndance since 2014= 297 (2023-24 = 0. 2022-23 - 0. 2021-22- 8}.
PETr altcndance since 2014.- 109 (2023-24 -0. 2022-23 - 0; 2U21-22 = 0).
2.1 U.? ,Siib Sa11aruii Al'i'ic
Angola. PETI Aiiendance since 2019 = 50. (2023-24= 0,. 2022-23 - 16- 2021-22 = 0).
Ghana in partnership with the Paediatric Socieiy of Ghana. During 2023-2024, one course was held. with 47 attendees.
Since 2018, the total number of PETI attendees is 311 (2023-24= 47- 2022-23 = 33; 2021-22= 11).
Kenya in partnership with the Kenya Paediatric Association. Durtng 2023-24, four PETI ¢our,ses were held wilh 184
atiendees and one PET2 course was held with 20 aiiendees.
PETI atÉendan¢e since 2017 49412023-24= 184. 2022-23= 48: 2021-22= 111.
PET2 attendance since 2020= 78 (2023-24= 20. 2022-23 = 39; 2021-22 - 16).
Page 8

British Paedlatrlc Neurology Associgtion
Report of the Trustees
for the Year Ended 31 March 2024
Mozambique. PETI auendanee since 2021 = 24 (2023-24= 0; 2022-23- 16; 2021-22- 8).
Souih Africa in partner.￿￿1p with the Pacdialric Neurology Developmeni Association of Southern Africa. Three courses
wcrc delivered by South African faculty in 2023-24. A iolal of 99 delegates attended the col1r.￿es. PETI allendance sittcc
2015-16= 478 {2023-24- 99- 2022-2023 = O- 2021-22 - 55).
Tanzania in partnership with the Paedialric Association of Tanzania. One course wag run in 2023-24, with 49 altcndccs.
Sincc 2018, tlie total number of PET l allendees is 233 (2023-24= 49- 2022-23 - 41. 2021-22 = 0).
Uganda in partnership with the Uganda Paediatric Association. During 2023-24, one PETI course was delivered to 34
delegales. Since 2018, the total numbei. of PETI attendees is 170 {2023-24 = 34. 2022-23 = 0; 2021-22 - 9).
Zambia in partnership with the Zambian Paediatric Association. PET was laun¢h¢d in Lusaka in May 2023, and faculty
from Zambia And Zimbabwe were trained. Since 2023, the loial numb¢r of PETI attendees = 62.12023-24= 62).
Zimbabwe in partnership with the Paediatric A5socialion of Zimbabwe. Faculty from Zirnbabwe weie trained at the pEr
launch in Lusaka in May 2023. Since 2023, Ihe total number of PETI attendees = 48.12023-24 = 48)
2.10.3. Asia
India in partnership with Raindrops Children's Foundation. PETI was launched in northern India in 2014 and southern
India in 2016. In 2023-24, seven face-to-face courses were held. Total PETI attendees in India since 2014: 1.634 (2023-24
336*. 2022-23 45; 2021-22 = 88).
*data not currently shared with the BPNA. This is an estimate based on the number of courses that were Tun and Ihe typical
number of delegates attending a course in India17 courses with 48 people each).
Myanmar- PET I was launched in Myanmar in 2014. Since then, 313 people have attended PETI {2023-24 = 0. 2022-23 =
O- 2021_22 = 0). Courses in the country are on hold due io the cuttent political situation.
Singapore in parlnership with KK Women's and Children's Hth%pital. Onc PETI course was held with 21 altendees. Sin¢e
2021. thc total number of PETI atlendees is 28 {2023-24= 21- 2022-23 = 0; 2021-22- 0).
2.10.4. Ccntral & Souih America
BraLil in pdrlncr%hip with Liga Brasileira de Epilcpsid. During 2023-24, four PETI courscs wcre held with a tolal of 75
dclcgates. PET2 launched in Brazil in 2023-24. One PET2 coursc was hcld with 24 delegates. PETI attendance since 2018
285 (2023-24 = 74; 2022-23 - 32,. 2021-22 - 40).
PET2 attendance since 2023 = 24 (2023-24= 24).
Colombia in partnership with Aso¢ia¢ion Colombiana de Neurologia Infantil and Universidad de Anlioquia. Two PETI
courses were held with 54 attendees. PETI attendance since 2021 = 132 {2023-24 - 54., 2022-23 63. 2021-22= 15).
2.10.5. Auslralasia
Australia in partnership with the Australia and New Zealand Child Neurology Society IANZCNS)
During 2023-24, two PETI courses were held with a tolal of 60 delegales and two PET2 courses were held with a total of
47 delegates.
PETI attendance since 2021 = 16712023-24= 60; 2022-23 = 94- 2021-22 = 13).
PET2 attendance since 2022 = 7112023-24 - 47. 2022-23 = 24).
Page 9

British Paedi4tric Neurology Asgoeiation
Report of the Trustees
for the Year Ended 31 March 2024
New Zealand in partnership with the New Zealand League Against Epilepsy and the Starship Foundation. During 2023-24,
two PETI courses were held, one PET2 course was held and one PET3 course was held.
PETI attendance since 2017.. 429 (2023-24= 41. 2022-23 = 83. 2021-22 = 25).
PET2 allendance since 2017.. 233 (2023-24 = 31; 2022-23 = 32,. 2021-22 - 31).
PET3 attendance since 2018.. 212 (2023-24= 32. 2022-23 = 54; 2021-22 = 0).
2.1 l. Evaluation of edu¢alional activities
BPNA'S edu¢alional activities are designed io promote the health and well-being of children with neurological disorders.
We are commilled to evaluating them to ensure that they do 50 and lo adapting them on an ongoing basis. After coniplelion
of any of our educational aclivilies, learners are required ro complete a feedback forni to assess their level of satisfaction
with the course. At PETI courses, learners also coniplete a pre- and post-cour5e quiz to assess knowledge-gain. and, six
months later. a follow up survey to establish Ihe changes that they have made io their clinical practice. These data have been
analysed by a group of researchers froni the BPNA and the University of Dundee and, in 2024, they were published in a
paper entitled Reducing epilepsy diagnostic and treatment gaps.. Siandardized paediatric epilepsy training courses for health
care professionals in the journal Developmental Medicitte and Child Neurology. We found that 98% of PETI delegates
change their personal clinical practice after allending the course and 64% change their clinical service. 68% iniiiate or
improve epilepsy teaching at their hospital.
We are working with the University of Manchesler to furEher refine our evaluation methods for the PETI course by using a
clinical behavioural-change methodology to furiher undersvdnd the impact of the course. It is hoped Ihat Ihese refjned
evaluation tools can be adapted and applied to other BPNA short courses.
Annual Scientific Conference
Oversight of the scientific content of the annual meeting, including absiracl scoring and awarding of the MacKeiih Prize.
rests with the Research Committee.
The 50th annual scientific meeting was hosted by Bristol and held as a hybrid eveni in January 2024. There were 726
delegates from 47 COLintries. Technology facilitated high delegare numbers {2023 Edinburgh-816; 2022=941. 2021-1,134.,
2020 BelfasiJ27) and geographic access. Opporiunities to learn were provided by 20 oral presentations and 217 posiers
{s¢le¢led from 250 abstracts submitted); 7 keynote lectures. 4 clinical practice sessions,. and 6 sponsored symposiums.
Page 10

Brltlsh Paediatric Neurology Association
Report of the Trustees
for the Year Ended 31 March 2024
2024 Prizes were awarded to..
Dr Dora Steel
(Ev¢lina Children's Hospital, London)
The Ronnie MacKeiih Prize. Awarded to the person who has
made the most significant contribution to paediatric neurology as
judged by published work and who is <40 year5 old or within 5-years
of obtaining CCT.
Dr Robert Spaull
(Great Ormond Street Institiile for
Child Health)
Best oral pitsenlation by a trair]ee.
Dr Susan Harvey & Dr Abigail
Lazenbury
(Great Omiond StreeL Hospital) &
(Southamplon General Hospital)
Best oral poster preseniaiion by a trainee.
Dr Alison Skippen(Oxford)
BPNA "BAFfA" Award for Fabulous Trainee Action.Awarded to
the trainee who has besl contributed to service improvement which
significantly impacled on iheir local andlor national practice or any
other innovative conlribuiion.
Miss Emily Gaskin
(University of Sheffield)
Best medical student presentation.
Dr Samantha Chan
(St George's Hospital, London)
Development Medicine and Child NeLirology IDMCN)
Besi Article by a BPNA Trainee Prize.
4. Pa(ieiil and Public Involvenicnl
We had 22 paediatric neurology related cliarities attended the conference. 18 were able to take up a physical Stand and 4
others took up the opportunity lo have a virtual exhibition stand to engage with BPNA members and the other allendees.
ppl
To motivate delegates allending Lhe conference physically to visit and engage with our exhibitors this year, stamp cards
were be provided. Delegates who collected 5 stamps from charity exhibiiors, had a chance lo win up to 4 £50 vouchers. The
aim was lo open up on the opportunity for charities lo engage wilh atiendees at the conference and identify opportunities to
improve the lives of children with neurological disorders. Each BPNA Conference venue has its challenges of where sland
spaces can be located, and the BPNA aims for charities to have as much involvemenl as possible with their stand location.
Feedbaek was received that stamp cards had a positive benefii bui ihere was room for improvemeni on engagement. The
BPNA look forward lo hosting the charities again at the 2025 conference.
A PANSPANDAS Working Group was sel up to discuss and liaise with PANS PANDAS UK in producing a PANS
PANDAS Working Group Sialement with other colleges and groups. This was published in February 2023 and addressed
the current variation across the UK in the management of paiienls presenting with Paedialric Acute-onset Neuropsychiatric
Syndrome (PANS) and Paediatric Autoimmune Neuropsychialri¢ Disorders Associated with Streptococcal Infection5
(PANDAS).
Since then plans for a PANS PANDAS Clinical Guidelines Development Group is lo be set up.
The BPNA constantly looks to expand the PPI throughoiit the organisation as part of the charitable aims. Request have been
made for PPI representation in the special interest groups, course development and as many other activities as possible. As
well as trainees should be facilitated lo work with PPI and social media. We proposed increasing this area going forward.
Pagell

British Paediatric Neurology Association
Report of the Trustees
for the Year Ended 31 March 2024
5. Research
The BPNA research committee has a remit for oversighi of the annual s¢ientific meeting as outlined above. as well as for
the speciality paediatric neurology session at Ihe annual Royal College of Paedialrics and Child Health meeting. The
research committee also oversees the development of research within the organisalion (o the benefil of children wilh
neurological disease.
The BPNA Research Colnmittee is chaired by Dr Sam Amin.
Members have a wide range of clinical and scientifjc expertise and come from a broad rallge of UK and Irish Paediatric
Neurology Cenires. The research commiitee has been working to develop the agreed research strategy of the BPNA,
focused on building research capacily within paediatric neurology and promoting research training within the paediatric
neurology Irainee community.
There is also BPNA Research ComTllittee represenlalion on the editorial board of Mac Keith Press for the Developmental
Medicine and Child Neurology IDMCN) journal. Two Regearch Committee members and three other BPNA members.
5.1 British Paediatric Neurology Surveillance Unil IBPNSU)
In 2(A)6, the BPNA sel up Ihe BPNSU to target surveillance of rare neurological conditions in a cost-effective and efficient
manner wilh the sample population being UK consuliattl members of the BPNA. Since 2006, 28 studies have been
conducted using BPNSU.
Dr Sukhvir Wright has taken over from Prof Richard Chin as BPNSU Lead in the Research Committee.
During 2023-24. 1 project was added onlo the BPNSU system (2022-23 0, 2021-22
2018-19=1. 2017-18=3). As of 31 March 2023 two projecls were active on BPNSU system.
1, 2020-21 =1, 2019-20=1-
BPNSU fees We￿ inctrased in 2020-2110 £1,200 for up lo 2-years, which is still significantly less than oiher surveillance
sludies. Additional years are charged £6(X) per annum.
The BPNSU website has been moved inhouse since summer 2023 and has been managed by BPNA. achieving ¢onlinued
update for the BPNSU email list and optimisalion of returns by the Membership Manager. Emails are sent out once a month
for notifications of new sludies.
In 2020-21, an audit of all past stLidies was carried out. Since 2014, there have been 15 conference absiract5 and 10
peer-revi¢wed publications resulting from BPNSU studies. Journal publications have been in Developmental Medicine and
Child Neurology, Neurology* and Lancet Child and Adolesceni Health. One PhD was awarded, and one Project reported 4
invited international talks in which BPNSU data were parn of the presentation. There were four 9uccessful grant
applications arising from BPNSU studies. with a lolal grant income of £1,237,949.. 1 MRC Developmental Pathway
Funding Scheme award, l NIHRIGOSH Clinical Fellowship, l KESS2 (Knowledge Economy Skills Scheme) Siudentship.
and a donation from the Alternating Hemiplegia of Childhood UK Charity. Public engagement varied from parental groiips
inforniing study design, results informing genetic counselling for families, to results being presented or planned to be
presented.
In 2021-22, the BPNA reviewed barrieis for applications and implemented the BPNSU Grant Award.
It was agreed by the BPNA Trustees to produce a BPNSU Grant Award for up to a 2 year study. This is eqiiivalenl to ihe
cost of £1200 which would cover the cost of a study 50 as lo suppori this charitable aim.
This grant would be eligible for a BPNA member who is otherwise a trainee or newly appoinlmenl consultant within 2 years
of qualifying.
The purix)se of the award is to promote research amongst junior members of ihe BPNA and to help create future researchers
in paediatri¢ neurology.
Recent aims has been lo promole BPNSU lo develop our relationship and try to collaborate with the British Paedialric
Siirveillan¢e Unil IBPSUI which is parl of the RCPCH. This is due lo having similar objectives and is ongoing.
Page 12

British Paediatric Neurology Association
Report of the Trust¢
ror the Year Ended 31 March 2024
5.2 Paediairic Neurolo
FLllow.qlii
A partnership was established in 2015 with Action Medical Research (AMR) io jointly fund a 3-year AMR-BPNA Research
Training Fellowship. Voluntary donations of members and income generated from sponsored symposia at the annual
conference fund this fellowship.
The second fellowship has been awarded to Dr Michael Eyre. Hi5 3-year fellowship was due to commence in September
2020, howevei. the start date has been deferred lo March 2021 due lo Covid-19. In his project, 'Developing magnetic
resonance measures of neiirobiological dysfunction in early recovery from NMDAR-anlibody encephalilis,, Michael will
investigate if advanced MRI techniques Can help predict recovery from NMDAR-antibody encephalitis in children and
young people, paving the way for new treatment approaches for the condition in future.
The third fellowship wa5 advertised and awarded to Dr Jonathon Holland, commencing in Autumn 2022. In his project;
Muliiple sclerosi8: assessing nerve repair in cliildren lo find out if they could benefit from new Irealmenls, Jonathon will
aim io find oul wheiher children with MS could benefit from potential new trealmenls currently being tested in adiilts.
A fourth Fellowsliip was advertised in Summer 2023 with the aim lo commence in Spring 2024. However, candidates were
not considered up io the standards and therefore the fellowship was not awarded to anyone.
The fourth Fellowship will be advertised again in Summer 2024 with the aim lo commence in Spring 2025.
The BPNA Research committee has designed a pre-selection questionnaire to support appli¢8nts.
Previous AMR BPNA Research Training Fellows..
2016-19 Dr Aposiolos Papandreou Neurodegeneraiive disorders with brain iron accumulation - finding new treatments.
5.3 BPNA Conference
The BPNA Research Commit￿e review, score and select submilled abslraclg, sponsored symposium and the Ronnie
MacKeiih Prize. Mac Keith Press co support the Ronnie MacKeith Prize and also support and se1￿¢ the Developmental
Medicine and Child Neurology (DMCN) Best Article by a BPNA Trainee Prize.
Prizes are also chosen and give by the BPNA for the Besi Poster by a Trainee Prize. Best Poster Audio Narrative by a
Trainee Prize, Best Oral Presentation by a Trainee Prlze and Best Medical Siudent Presentation.
5.4 Read of Ilie monili aiid Traince
nf Ilie niiinili
A5 part of the BPNA Newsletter, every month, a different member of ihe BPNA Research Committee will choose a recently
PLiblished. topical paper relevant to Paediatric Neurology, Neurodisability or Neuroscience, that Ihey think woiild be of
interest to the BPNA membership.
Also every month. a recent publication that has either been led by a BPNA Trainee (or where a Irainee has provided
significanl input) will be highlighted.
6. Professional .Su
rt
There is a high demand for Professional Support. One full lime slaff member Imembership Manager) oversees the
department. Dealing willi menibership requests, mentoring capacity, organisaiion of meetings for Special Inieresi Groups
and supporting Trainees with (heir development. The Professional Support Officer (Trustee) is responsible for the
department and meets regularly with the Membership Manager and Director to make sure areas that need development are
progressing including job planning, mentoring, charity involvemenl (PPI). Census and Paediatric Neurology recruitment.
Page 13

British Paediatrie Neurology Associatlon
Report of the Trn$te¢5
for the Year Ended 31 March 2024
LI BPNA member%l)i
Membership numbers have inereased sleadily during 2023-24, supported by the Membership Manager, Katerina
Roumelioli. A new eategory of membership 'Allied Health Professional, was introduced in recent year.8. This category has
minimal subscription fees io encourage engagement and no voting rights. The BPNA also added Medical Studei)t
membership with £0 fee to engage with young people with an early interest in Paediairic NeLirology. Criieria to be accepted
is a confirnialion letter from associated University thal i.q resent each year for membership renewal.
BPNA Membersai March 2024
700
5(Al
52
Icw
14
)ni
16
?ni?
?n1P
?oJn
)n?t
?0)4
?n?4
nrAlnary # n¥•r￿ls
Membership Numbers
2024
2023
Catsgory
Ordinary
Overseas
2022
382
376
342
75
72
72
Trainee
125
126
118
Senior
70
66
Honorary
AHP
10
51
26
Medical Student
Total
715
705
636
Page 14

British Paediatric Neurology Association
Report of the Trustee5
for the Year Ended 31 March 2024
(1.2 Mciiloi'iii
,Ind TLcllil Sli
)orL
In 2015-16 Trustees identified a need for members to have access to mentoring services, and it was &￿eed that ilie BPNA
shoiild Contribute to fLilfilling this need. The nientoi'ing programme began in 2016.
During 2020-21 the mentoring programme was expanded lo p4ediatric i)ellrology and Neurodisability GRID irainees wiiliin
12 Tnonthb of ccr to piovidc additional supporl through the pandemic. As of 31 March 2U24, Ih¥tL (LfL 42 BPNA mcmbcrs
volunteering as mentors (2023-39) wilh 29 mentee.q (2023=50) wilh mentors now taking on two mcntee.q.
In Novcmbcr 2023 BPNA COTllTlliS5ioned a Mentor Consultant lo deliver a training day for menlors for a fourth lime. The
tt7ining tiiught different models of menlorship and wa% Ycry well rC￿lvcd. Th¢ ahm woiild bc lo do ihis evcry year but
rcvicwing developniciit for both mentors and mentees and how ihis area can evolve.
DLiring. 2023 ibc Tnenloring programme w(￿ cxpanded for more senior CPN8 who requEsled Tnare Tnentors lo support Ihcm
through career stageb, such as post moves, return from parental leave, rel1￿Me￿l etc.
The mentoring and iiientee program is being reviewed in was it can be developed for the workforce of the BPNA
membership.
Invited Reviews
In Slipport of the BPNA charitable aims, BPNA Invited Reviews offer assistance to healilicare organisations in addressing
concei'ns and ¢liallenges relating to care for children with neurological ¢ondilions.
"The primary pui'pose of an invited review is lo piovide expert opii)ion and external assurance around quality of care that
may lead lo improvements lo patient safely and service provision. Invited reviews are designed io facilitate reflection and
learning.
Academy of Medical Royal Colleges 'A framework of operating principles for managing invited reviews
within liealthcare, (March 20221,.
BPNA Inwiled Reviews are conducted in accordance with the principles sel oiil in the Academy of Medical Royal Colleges
(AOMRCI 'A framework of operating principle5 for managing invited reviews within healthcare, (Marc11 2022).
The BPNA has prodiiced A GLiide to BPNA Inviied Reviewb, available on the BPNA website, which explains the
slrLiclured, clear and consistent process that we lollow.
No Invited reviews happened this year.
Page 15

British Paediatrlc Neurology Associatlon
Report of the Trnstees
for tht YeAr Ended 31 March 2024
6.3S
ecittl Inlcre%t Gioii
.qIVi
For the SpLcial intcrcst group.s hybiid working makes it mole accessible for people to join online or person depending
liow their meeting is arrangcd. Some face-lo-faLc meetings happen but due to the 8i/.c of the group% onlinc meetings arc
more beneficial for peoplc lo attend.
The BPNA also iipdaled their website for each SIG page to inform about Trials and i"esuurcc documeni% r(Ir ihcir members.
6.4 Bi-ilisl) P<iedi<iifiL F. ilL
GI'OLI
Mcnibers of this SpeLial Interest Group have particular expertise in childhood epilep%y. There are over 100 mcmbers
which includcs pacdiatri¢ neur()lthgi.%ts, pacdiatrician.q wilh an interest in Lpilcpsy and clinical nursc specialA814. Thrcc
mcctings have beeii hcld in June and Novembcr 2022 41nd March 2023. The focus of the nieelings ha5 becn on the
development and implementation of guidelines for epilepsy in childrcn. to share updales in audit and research in paediatric
epilepsy, to explore opportunities for the professionals to network and to discuss anonymised complex and ediicational
cases.
The BPEG IBrilish Paedialric Epilepsy Group) Chair and members have contributed to the following parti¢ular aspects of
childhood epilepsy..
Cannabidiol and CBMPS
Ongoing liaison with RCPCH, NHSE and stakeholder charities on issiies related to prescription of cannabis-based products
for medicinal iise in children and young people with epilepsy. BPEGIBPNA have had meetings with APPG chair for
prescription of CBMPS and Patient Safety Commissioner io discuss these issues. RegLilar BPNA CBMP group meetings to
review press and media requests about CBMPS.
Sodium valproate
SinLe ihe announcemeni of MHRA statemeni on new restrictiong on the prescription of sodium valproale, we have actively
engaged with relevant siakLh()Iders such as tpilepsy charities. A%%ociation of British Ncurologisl8. and OPF,N-UK to
di8eu44 potential implicativns. We have wrillcn lo MHRA expre%sing our concern.4 potential ri8k% for patients wilh
epilcpsy. and requested a mceling with MHRA to discuss our conccrns and sugge%livns tor safe impleTncntation OF any
chan¥cs. We have also formcd a working group with ABN membcrs lo address the issuc of changes lo sodium valpn)aie
pre%Lription.
.Stakeholder Charities
Eiigagcment wilh siakttholdcr charities. in particular addirsbing ihe issues of pre.%Lription of sodium valproate 1¢ nd CBMPS.
NHSE Epilepsy Qversight group
Provided oversight on developing national bundles of care for patients with epilepsy a5 pai'l of CYP Transformation
Programme.
Led on development of national bundle of care for transition to adult care for CYP with epilepsy.
Faeilltating research in psediatric epilepsy
BPEG provide5 the platform for colleagues from acro8S the UK io present their research, facilitate collaboration and setting
up a dedicaied page on BPNA website with informaiion on epilepsy research projects.

Brit15h Paediatric Neurology Association
Report oc the Trustees
the Yellr Ended 31 M2r¢h 2024
C]inlcal Nurse specialists and paediatric neurology trainees
B?EG have encouraged ¢ontribulion of clini¢al nurse specialists and Advanced Nurse Praciilioner in childho(xl epilepsy and
requested for representslion in the group.
B?EG have encouraged particlpation of paediatric neurology iraine¢s and epilepsy SPIN trainees and r¢quesied for
rq)reseniation in the group.
Additional meetings regularly attended with contributions from BPEG:
Epilepsy 12 Audit programme.
Open UK Network Meeting.
Epilepsy Programme Board (led by RCPCH).
RESCAS.
6 5 Cei'ebi'ovtl8ciil<ir S
ecial Intere.41 GrnLI
T.iis group s interest is in ihe clinical area of neurovasculai. disorders, such as paediatric 51roke and other vascular disorders
a￿eCtIng the central nervous system. The lack of a database 18 seen as a major obstscle by colleague5 and efforts conliniie
to resolve this.
T.ie group men)bers are going to Tneet next in June and following that in the autumn. Dr Alwis has accepted lo be the
group's secretary and we a150 have trainee representatives within (he group.
I'e continue to work alongside the Stroke association in highlighting the inequity of slroke care in some regions and
inproving access to treatments in a timely manner.
1.6 Childreii'$ 14Lad41¢1ie Neiwiirk Cl-liiN
CIIAN has continued io remain very active over ihe past year to advance the clinical management, educalion and research
ir. primary ai)d %econd&ry childhood headache disorders.
Although there is an appeiile lo resun)e face to face Tneeling. we plan to have the next meeting in autumn 2023 as
rc.mot¢lvirlual.
There remain5 a clear 51ructure of the role5 Wlthin the CHaN network on a narional level with dedicaEed responsibiliiies io
n-.embers for providing clinical, research and acadeTnic updates.
CHaN also recognises the need to develop national regislries for patienls with conditions like Migrainel TACS and
U1common headach¢s. Specialist groups within CHaN such as IIH SIG group and the CHAT course development network
ci)ntinue to develop educational materials and guidelines le.g., Ihe paper by Holland et al. on 'How lo perform Lumbar
p.InctLire in children.
and the paper by Dr Prabhakar et al. regarding the 'Assessment and management of children with
aLUte headaches,) both recently published in the Archives of Disease in Childho¢)d
_ims for the next year:
Benchmark the ciirreni practice for management of episodic and chronic migraines in the UK with identification of key
paediatricians, so that a gap analysis can be made
Closer and wider engagement with various Iieadache charities {like The Migraine Trustl The Brain Charity) to fund data
bases and educational tools
Encourage iraineeb, participation in the distance learning module
Page 17

British Paediatric Neurology Association
Report of the Trustees
ror the Year Ended 31 March 2024
. l. Fctal & Neunalal Neurolo
Spccial Iiitcrcst Grou
The PLrinatdl Special Jnlcrcsi Groups haq a sliong edlicalional theme, and continues to provide educalional meeiings twice a
ycar in neonatal and fctdl neurology. Thesc have been dclivcrcd virtually %incc the COVID pundemic. and draw a range of
health c￿e prol'essionals, including Iherapiqis and nurses, IroTll around the UK and beyond. Mcmbcrs of Lhe SIG have
worked with ihc BPNA executivc to relaunch ihc NeoNATE cour.%c. which was on hold following ihc pandemic, and two
courses are planncd in 2023-2024. Wc are looking lo increase our tcaLhing faculty iii the coming yLar. We have had a
initial planning meeting for the BI'NA Fcldl coiii'se. whiLh aims to providc cdiicational matcrial on fetal neurological
anomalies and antenatal counselling. A preliminary programme has been pr()duccd and talks ai"c currently belng wriltcn. We
plan io meet in Autumn lo rcview progress.
Inteinatii)nally, we have had Tneetings with perinalal neurology ¢ollcagues in Ihe US, and plan to collaborate on edii¢aiion
meeting8 and sctvice recommendations. as well as building our contacts in Europe. Wiihin the UK, we have continued our
work with the British Association ol Perinatal Medicine on gliidelines, on this occasion recommendaiions for neonatal
neiiroimaging.
Clinically, the BPNA exe¢iilive has agreed for us io proceed with an illiliative to develop patient informaiion leafleis on a
range of fetal neurological anomalies, and a working group is being created. We also intend to discuss how we can collect
data on genetic diagnoses and outcomes loo, which would infom) and improve future prognostication.
Menibers of the SIG remain research active in a range of ideas. including MRI appearances and neuro-developmenl
ouicomes following neonatal hypoxic ischaemic encephalopathy, families, views on anlenaial counselling, and a new
profoma for the neurological examination of the unwell newborn baby.
6.7.2. Inlicriled Wliite MaiiLr Di%ordei's
LLuki)(I
New National Service for Inherited White Matter DSsorders (IWMD) elinical registry
NHS England has recently commissioned a ncw highly specialised service for Inherited While Matter Disorders IIWMDS)
and also a separate National IMWD clinical registry lo siipport ihis.
NHSE has commissioned 3 paedi¥?Iric and 4 aduli centi'es to provide the IWMD service. NHSE has albo contracted with
Evelina London Children's Hospilal which is part of Guy's and St Thomas, NHS Foundation Trusi, 10 hosi the Naiional
IMWD clinical registry.
A core element of the registry is the managemcnt of online gcLure databasc thal contains information about pcople of all
agcs with suspeclcd or confimiLd IWMD. We aivn lo iise this registry to support the provision uf direct paLienl trcatment and
care and improvements lo clinical carc. This will help us to.- undcrstand the inLidcnce and prcvalence of IWMD in our
population. improve t)ur understanding of the naiural history of vurious IWMDS, mcasure ihe impact of Ilving with an
IWMD for paticnts and carcrs and create morc awarene45 (Trf these conditions.
Thi5 regi.glry is Uniqlie as this is both clinician and patienl drivcn. The primary aim of this registry iq for clinical purposes.
however, this Icgi&lry will ccrtdinly provide importani daia for future rescarch for patienls wiLhin the ficld of IWMDS.
The regiqlry will work very closely with 3 other paedialric IWMD clinical service ccnlres ILeedslManche8ter- lid by
Profcssor John LivingslonlDr fjipdk Ram, Birmingham led by Professor Evangeline Wassmei. and t)r AJnitav Parida and
London (GSI'T and Great Ormond Street) lcd by Dr Rahul Singh/Dr Cheryl Hemingway) and the aduli cenlre {London,
Queen SqU￿.e Hospital-led hy Dr David Lynch) in collaboration with units in the north dnd Midland%.
A formal launch of the IWMD I'egistry servA¢e will lake place laier in the year. The registry is in the piloi phase now and we
expect this will be live soon.
We would accept referral.s from patients, parents or carers, clinicians involved with the IWMD patients, and frotn
iieurologisls. paedialric neurologists, geneticists, metabolic physicians, geneticists, paediatricians or any local Clinicians
involved in the diagnosis or treatment of IWMDS.
Referrals will also be accepted from fetal medicine ieams, when ihere is a strong family hisLory of an IWMD and we will
also facilitate rapid diagnosis for conditions where ihere is a ireattncnt option (c.g. Metachromatic Leukodysu'ophy).
Page 18

Brltish Paediatric Neurology Association
Report ol the Trustees
for the Year Ended 31 March 2024
The charities Alex TLC (www.alextlc.org) and Metabolic Support UK (www.melabolicsupporluk.org) have been closely
involved in the development of this regislry, will continue lo support the registry and will be an integral parl of the IWMD
registry steering and development committee. We plan that Ihe new service will be fully operational in the coming months.
In the meantime, if you wish to request fuiiher information ple&se contact.. gst-tr-IWMDR@NHS.Net
6.7.1. Bi'iLi.%li Paediati'ic Movemenl Di%(Irder S
eeial InlbrLS1 Groi
The last year has been an a¢tive and successfiil year for the SIG. In addition to regular virtual meetings. the SIG held a
well-attended meeting al the Bristol Conference focussing on the development of guidance for parents and carers on video
recordings of Movement Disorders. This was in addition to a very constrnctive Research focused meeting on how lo address
the findings of the BPNA Priority setting Project. The SIG will continiie to me¢t largely virtually for 202412025, with at
least one FIF meeting al the next BPNA Conference in Oxford.
Education continues to be a major focu.s of the MDSIG. Thi5 year saw the successful launch of the MovEd course. delivered
by an expert faculty led by Dr Lucinda Carr. The fir51 course ran over 2 days in October 2023, with excellent feedback. We
thank Il)e faculty for all of their hard work producing such an excellent educational resource. The ACT course has wntinued
to run with similarly excellent feedback. The course leads are committed Lo expanding the faculty of boih cours¢s, and I
would strongly recommend this to MDSIG members as an extremely satisfying experienced. Focus will now tun) to
completing the over-due re-write of Unil 4 of the Dislaiice Learning Course, along with the developmenl of ihe planned
Expert-to-Experl Movement Disorder course.
Work has continued on Guideline Development. The Consen%u5 Standards on Medication Use in management of Childhood
Dystonia project has launched, and al the lime of writing is close lo completing the initial stage of Collection of suggested
standards. This project, sponsored by the BPNA, is a joint venlure with the British Academy of Childhood Disability and
the Association of Paediatric Palliative Care Medicine. along wilh other stake holders. The next stage will be to undertake a
Delphi process based upon tlie suggested standards received. Similar work around the referral of children for consideration
of neurosurgical interventions will move shortly to Il)e Delphi stage. A FtF meeting is planned later this year io begin to
exploi'e patliways of care for Children and Young People with Reli Syndrome in light of the emergence of gene therapy
trials for this condition.
Members of the SIG have expressed understandable concerns about the stability of supply line for commonly used
medications. Discussions Continue with the Neonatal and Paediatric Phamiacy Groiip and colleagiies across ihe BPNA and
the Association of British Neurologist (ABN) about how best to "horizon scanning" for such problems. The SIG 15 currently
Iindertaking and audit across several centres on the use of transdermal clonidine patches and is supporting the development
of guidance foi. the use of patches.
Work with transltion has progressed. The BPNA and ABN have re¢ognised this as a priority, and will be hosiing a FtF
meeting later this year lo identify areas of priority for both groiips. The MDSIG will be well represented at these meetings.
May 2025 will be the end of my second ￿rM as Chair of tl)e group, aT]d throughout the coming year we will be looking to
identify a replacement Chair. Dr Raj Lodh's second term as SeciElary will also being coming lo an end at ihat time,
providing another opportiinity for BPNA members lo contribute more forn)ally to the working of the SIG.
6.7.4. MLI.4cle Iiilei'esl Gi-oii
The muscle SIG works closely with the neuromus¢ular charilies, in pariicular the Muscular Dystrophy UK {MDUK), Aclion
Duchenne, Duchenne UK. SMA UK. DMD HUB. These parinerships have helped accelera￿ research - funding research
fellow posts, access lo clinical trials, improved Siaffing at peripheral sites for trial set up, helped coordinate regional
neuromuscular networks and upskilling events and Slipporled meelings lo improve standards of care and data colleciion and
dissemination. The centre of excellence audits took place in 2023 and were awarded to ¢¢nlres in 2024. 24 ¢enire awards
in lolal. 16 10 those with clinical excellence with research. 3 with clinical excellence and 6 pursuing awards in clinical
excellence +l- I'esear¢h.
Page 19

British Paedlatrle Neurology Association
Report of the Trnstees
for the Year Ended 31 March 2024
This year key involvements have been with SMA UK and MDUK in helping to Continue the delivery of the MDT in SMA.
including Zolgensma, risdiplam and nusinersen following approval by NLCE NHSE on 8 March 2021. The lasr 12
monihs have been focused on working towards newbom screening whi¢h will change the prognosis and ouicome8 for the
children with SMA type l. The infusion sites are well established and the national MDT rlinning since May 2021, and over
100 ctlildren have received gene therapy.
All ihe SMA children have been followed up and various webinars and meetings have been held with ELiropean colleagueq
on side eff￿(S and problems aSsocia￿d with gene therapy, as well as forum meetings face lo face planned in June and
November 2024.
From the Norihsiar group., Work has been conlinuing on AialuiEn and enabling access for this drug after EMA renewal was
not siiccessful in September 2023, but NICE approved Ataluren 22 February 2023 via HST22 committee. There are also
ongoing submissions to NICE and NHSE for Vamoi'olone and Givinostal, both non-mutation specific drLigs for DMD.
HUB DMD. has continued close working with clinicians to enable trial readiness and liaison with the pharma companies to
look at what is needed per sile to continue trials. Trials are now continuing and furiher set up of sites for new studies liave
commen¢¢d.
As a SIG we have coniiniied in 2023 and 2024 10 meet regularly virtually and full day face lo face muscle interest group
meeting planned for 14th June 2024. Both paediatric and adLilt Northsthr meetings IDMD) and paediatric and adult SMA
REACH meetings (SMA) have continued virlually thig last 12 months, especially developing the adult SMA REACH.
British Myology socieiy was face lo face as was the Translational research meeting UK and World mLiscle society meeting.
The muscle interest group has met 4 times in tolal 2 fully virtually and 2 meetings face to face Iparl of BMS and standalone
day in June 2023) for case discussions and iopic led presentations over the last 12 months.
The RDCN (rare diseases collaborative networks) accredited the Juvenile Myasthenia (JMG) Gravis group in 2023 and this
continues to be hosied by the designated providerg. Oxford specialist service, and this groiip io have virtU81 meetings for
dtfficult cases with JMG.
The charities also sponsor, the muscle group's main annual meerings such as the British Myology society. Translational
research meeting UK, Northslar and SMA REACH meetings within the UK. The meetings also receive unresti-icted
educational grants from pharmaceuLical companies. We work together with the clinicians on various paiient iniliaiives-
patient leaflets, e-learning modiiles, patient days, Children's transiiion days and camps- and support the various
neuromus¢iilar ￿amS in their individual areas. such as NM networks, local educational meetings and trial set ups.
Lastly, we are working with colleagues both trainees and Consuliants to lake a closer look al training and how we can
increase opportunities and interest in training in Neuromuscular disorders. This year we have appointed a MIG trainee
representative Dr Alison Skippen and at our next face to face meeting on the 14th of June in Birn)ingham. we have a session
dedicated to discussing this aspect.
6.7.5. NeiiroLiilanLous S
Cl&il IiilerLs1 Groii
This groiip's interest is in the clinical area of neumcutaiieoiis syndromes. such as Neurofibromalosis, Tuberous Sclerosis
Complex and Sturge Weber Syndrome. This is a relatively new group who has been running for about iwo years. We are
meeting twice a year which are a mix of viriual, hybrid and had an in-person meeting during the BPNA conference ihis
year.
The neurocutaneous SIG has been supporting paedialric neurologists and paediatricians across the country with informaiion
about ihe different syndromes. Members have been involved in supponing and giving information to stakeholders and io
families ai support days hosted by charities. We have algo Completed a survey into the use of vigabatrin iwb TSC and will be
discussing next sleps in our next meeting.
As a group we are keen to discuss and share informalion about upcoming research and new Irealmenis. We are keen to hear
from leading experis from across the UK lo share knowledge and experience.
Page 20

British Paediatric Neurology Assoclatlon
Report of the Tru5lees
for the Year Ended 31 March 2024
ACHIEVEMENT AND PERFORMANCE
FundrAlslng actlyitles
6.7,6. Ti'aiiiees, S
CLIJI Ii)ierL%I CJrL)u
The BPNA Iraine¢%' special inlcrcst group ISIG) is a group for all BPNA trainee members and those interesied in paediatric
neurology training. Currently there are 129 Trainee members, including paedialric neurology subspecialty trainees (GIUD),
paediairic trainees of different grades, and other Irainees interested in paediatric neurology. The group meets twice a year,
once ai ihe BPNA conference in January and once al a 2-day educational trainees, meeting held in May. In May 2023 our
meeting covered Paediatric Neurogenetics, in which our excellent speakers educated on all things genomics, geneiic
Iherapies. and neurocutaneous syndromes. The Stuart Green Memorial session was a maslerclass on clinical examination in
paedialric neurology given by Dr Peter Baxter. We have just concluded the May 2024 meeting which was split between an
update on Neuroinflammation, and a Research Matters training day. Prof Ming Lim gave an inspiring Stuart Green
Memorial lecture, and we enjoyed talks and inleraclive sessions from an excellent speaking line up. For boih years. over 40
attendees were present, mostly in person, and all enjoyed an excellent dinner and social evening. We are very grateful to the
many excellent speakers who gave their lime for Ihese events. Recordings of sessions are available to watch An the BPNA
Trainees, SIG area of the BPNA websits.
The Research Matters training day deserves further mention - this was co-organised with Dr Sukhe Wright and the Research
Committee, and we are very grateful for the support of Dr Sam Amin for this day. The 30 attendees in person and 12 online
heard a wide array of inspiring speakers, and participated in workshop sessions on developing a research question and
writing a research proposal. The faculty included BPNA research Committee members, consultant paediaLric neurologisis,
an expert on PPI neurological disorder lived experience, members of Action Medical Research and Epilepsy Re5ear¢h UK,
and trainee members.
The SIG a180 contributes lowards the BPNA Recruitment working group aiming lo improve recruitment lo paeiliatric
neurology specialty training, We continue lo run annual pre-appli¢ation and interview webinars for neurology and
neurodisability applicants, which have been well-received by EK>th applicants and CSAC interviewers. Recordings of these
sessions are available on the BPNA website careers section. Overall, recruitment has moved into a differenl phase, with a
higher applicant lo place raiio than previously rel]ecting in part the efforts of the working group - this is a good time to put
out a specially training post, so please do work wilh your deanery training programme directors.
In Oclol)er 2023 we ran a first joint event with ihe siudenl group NANSIG who have presence in every medical school
nationally - this Saturday morning online session was attended by over 50 interested medical students and foundation
doctors. In addition, medical students can now join the BPNA for free. and we are working lo increase inleresl at earlier
stages of training. We will continue to work with NANSIG to extend our reach with do¢tors and tnedical students at an
early stage, to increase awareness that neurosciences can be fruitfully pursued within paediatrics.
The results of the 2023 paediatric neurology subgpecialty training annual survey were presented at an RCPCH CSAC
meeting and aT] anonymous summary of resiilts was sent to all training ¢enlres. Issues highlighted as of particular concern lo
training include workload difficulties. difficulty accessing several ar¢as (neonatal neurology, neuropsychAatry, and adult
neurology). limited access to clinics, and limited or inequitable access to research opporlunilies. With CSAC we continue lo
work on these issues where possible and support individual trainees al and between their annual review meetings.
The SIG continues lo successfully set up and support study groups for modules of the BPNA Distance Learning. Trainees
report Ihese provide excellent support and motivation lo complete modules. The groups are open to all trainees and recent
groups included neurology specially trairsees, epilepsy specialist inlerest (SPIN) trainees, trainees from abToad, and recenily
qualified consultants completing units lo complete SPIN accreditation. Many of these groups have very kindly been
supported by consultanLs offering their lime lo supervise and facilitate the sessions during their weekly meetings.
Finally, we would like lo congratulate the election of Dr Aiidrey Soo as chair and Dr Abigail Lazenbury as depuly chair of
the SIG going forward. We were very pleased to have eight applications for the roles, reflecting the engagement and
enthusiasm amongst our paediatric neurology trainees, and Tom and l are confident the SIG 15 in excellent hands going
forward.
Page21

British Paediatrle Neurology Assoeiatlon
Report of the Trustees
for the Year Ended 31 March 2024
ACHIEVEMENT AND PERFORMANCE
6.7.7. UK-Cliildliood Inlldiiiiiilllor
Deni
This group's interesi is in the clinical area of acquired intlammaiory white matter diseases (such as paediatric onsei Muliiple
Sclerosis, MOGAD and AQP4 antibody driven disorders and the autoimmune mediated encephalitides) as well as other less
common inflaTt]matory brain conditions.
The past 12 months has continued to be a busy for the paediAtric neurology acquiiEd and inflammaiory whitc matter group.
We have met regularly, as before, every 2 months. The meeting5 have all been virlLial, chaired by Paed Neurologisi Cheryl
Hemingway and with administrative support provided by the BPNA and hosted on the BPNA Zoom platform. Clinical
adniinistralive support has been provided by GOSH PA team.
The 6 meetings have been well attended, wilh arnund 40-
50 individuals joining, wilh both national and iniernalional represenlalion. The meeting forniat has continued as before,
with the fjrst hour ¢onsisling of upda￿S and formal presentations, and the next 3 hours discussing clinical cases. We have
dAs¢ussed on average 10-12 clinical cases pei. meeiing. The meeting has been excellenily supported by expert
neuroinflammatory colleagues around UK and has had expert neiiroradiology from Giral Ormond Street. and we thank
partieiilarly Dr Kshitij Mankad and Dr Asthik Biswas for iheir time.
We have as before kept the formal slandard as follows:
3rd Friday of every 2nd month
Time: 1-5pm
Video-conferencing via Zoom
First 60-90 minutes involves updates on researchlnew medicationslclinical challenges then
Brief comfort break
Next 90 minutes discussion of clinical cases with radiology review and forniulation of a suggested invegiigation andlor
Ireatmenl plan
The meetings have all been experily documented, and I would particularly like lo thank Dr Eyre, Dr Abdel-mannan and Dr
Perry and Dr Holland.
We have in tlie meeting had a number of excellent presenlaiions and also had regLilar research updaies from the fellows in
neuroinflammation. The talks at the meeilngs have been recorded and are available on the BPNA website for ihe SIG
members.
In May 2023 Cambridge hosted the UKCNIDINHS England HSS (Highly Specialised Service) paediatric onset MS
me¢iing. Atlendees included Paediatric Neurologists, trainees in neuroinflammation, specialist nurse,s, researchers and NHS
managers from Birmingham Children's Hospital. GOSH, Evelina Children's Hospital, Royal Manchesler Children's
Hospital, Addenbrookes, Alder Hey aT]d NHS England, University of Oxford, and Birmingham University.
The disease management guidelines, patient inforn]alion sheets and disease modifying drug gLiidelines were also compleied
and many have been uploaded lo the NHSE Plaiforni
We will conrinue to meet over the nexi 12 months. with another face Éo a face meeting planned for May 2024 and hosted
this year by Manchester.
The next 12 months the dates we are due to meel as follows..
17 May 2024 (national meeting Manchester)
19 July 2024
13 September 2024 (moved because of EcfRIMS meeting)
15 November 2024
24 Janiiary 2025
Page 22

British Paediatric Neurology Association
Report of the Trnstees
for the Year Ended 31 March 2024
ACHIEVEMENT AND PERFORMANCE
(?,7.8. LIK NeLlI'oreliiibilita(ion .S
eLial Inici'csl Groii
The pa¢diatriL neuroirhdbilitalion SICJ is a mul¢JdisLiplinary group supported by represenlalivcs frojn England. Scotland.
Wales and Northcm Ireland.
We aiTll lo..
Share gn(Kl praLIiLc
Dcvclop an cquitable paedialric ncurorchdbilitation service nalionally
Support rescarch and improve the evidencc base in paediatric neurorehabilitation for acquired CNS injury.
Link Wilh other groups (third seclor) and parents l users affected by acquired brain injury
Tlie SIG continiies to be Cliaired by Dr Peta Sharples. This year we have continued lo work closely wilh Ihe Paediatric
Neuroscience Clinical Reference Group whose agenda priority is currently Paed Neurorehailitation.
Paed CRG Neurosciences
ich of our meetings has heard updates from the CRG Chair (Charlie Fairhur5t) and Anthony Prudhoe (Women and
Childrens NHSE Manager) relating to the review of the National Service Specification for Paed Neurorehabilitaiion. In
order for them to be satisfied this specifiealion review will meet the needs of our CYP population they have had significant
engagemeni with our providing teams and visited several unils. We await the final consulialion.
Meetings
Kings Dee 2022 (Host) - theme paediatric spinal cord injury and the national transformation review. Speakers included Dr
A Graham Services for CYP with acquired spinal cord injury - several units described their new Children's Spinal Cord Case
Manager pos(s and Ihe London team ( speaker Anna Majowska ) shared Iheir SCI commi85ioning strategy.
Oxford Mareh 22 (Host) - theme innovative tcchnology on applied lo Acq brain injury, including immersive virtual reality
sy.slemb. Jill Cadwgan Spoke about Ihc Twoean Study A pioof of concept sludy of using wrist worn accelerometers lo
enLouragc affected Lipper limb Tnovcments in children wilh unilatcral cerebral palsy. Infonndlion was also shared aboul ihe
NIHR Innovation Observatory hurizon scanning research rc¥uiding tcchnology for Paediatrie TrauTna care and Rehab.
Ncxt meeting Aulumn 2023 Date tbc. Areas of ongoing concern (amongst many) bcing itansition with a childhood ABI to
aduli hood and also the challengc of finding optimal servicc5 if 5Ublaining an acquitted brain injury bclwccn 16-18 .
6.11. Clinical Governance
IIPNA has been conslilied hy NHS NICE lo comment on gllidclines and quality standard% and by NHS F.ngland lo comment
on Ihc ncw ijrug Irealmenls. If you would likc niore informauon about which ol these the BPNA have contribulcd please
contact the Director.
Internal and external factors
Ri.4k niaiia
The trustee% have assessed the major strategic, business, and operational risks to which the Association is exposed and are
satisfied iliai syslems and procedures are in place io monitor and contro_l those risks to miligate any impact they might have
on the Association. A risk register is maintained and updated regularly.
Page 23

British Paedlatrlc Neurology Association
Report of the Trusteos
for the Yesr Ellded 31 March 2024
ACHIEVEMENT AND PERFORMANCE
PrinLi
al risks wid UiiLei'lJiiilie
We have currenlfly idcntified the following factors as being the main risks io the BPNA..
Pressure from NHS Tru%ts on 14PNA members lo incrLa%c ihe number of elitlicslpaticnts and limil other activitics.
This has ihc potcniial lo impact on ihe vulLintary time given by BPNA membcrs to lecture, tiitor and mcntor at
short-courses, dislance-learning, aiid nicntoring. Our consultant members have remaincd robust and enthu.qia%lic in
Ihis support, and we hopc that this will remain the c&qe, but il is clear that the BPNA would be unable to conliniic i
delivering edlication withuui thi& gcneroiisly donaled lime. This is being monitored by Educ<ltion, QLiality &
Standards committcc and Professional Support Commillce wilh (he aim lo start a faculiy retention workin¥ group
this year to research and review the risks.
Repulalion ITr bcing associated with unprofcssional or unethical or even criminal a¢livilies in the UKlabroad due lo
disengdgeTnent about hot tOPlC ISSLies. Thi% can bc hi￿]I1ghted in recent ycars on cannabis-ba,sed medicinal producls
(CBMPs} and Pdediairic A¢iite-Onset Neuropsychiatric Syndrome (PANS) and Paediatric Autoimmune
Neuropsychiatric Disorders Asbociated with Streptococcal Infections {PANDAS).The BPNA has worked hard tn
engaging with such issue5 and producing Iheir own or collaboration with other professional colleges to produce
working slalemenls..5imilar issues will no doubt arise in the future and the BPNA must engage with those groups to
be seen as professional and supportive while noi putting Jnore pressure on the BPNA members and wider medical
professionals in the paediatric neurology community.
The BPNA should hawe been historically VAT registered and there is a review by the accountants on how much will
need io be paid back to HMRC. This will change the balance of Ihe reserves by next financial year and operational
objectives may need lo change
FINANCIAL REVIEW
Finaneial position
The balance sheei posiuon shows net cu￿en1 assets of £942,150 (2023 £922,236}, resulting from a stgntficant increase in
the cash al bank co £1,053,537 12023 - £981,135). T1)is has been accompanied by an increase in debtors 10 £65.203 (2023
£40,051 I, and increase in creditors to £185.253 (2023 - £110,01 I ).
At the year end the charity has unrestrieled freely available current reserves of £764.45912023 £909,160) which excllides
(angible fixed LsseLs of £21,243 (2023 £10,402). Givcn thc Lharily's curreni levcls of expenditure this would allow for
approximately jusl uvcr seven months 12023 icn months) of trading without further freely availablc reserves becoming
available.
Principle lunding sources
Th¢ BPNA raisc5 funds mainly through payments received for Ils cducational activities, which include shorl-coiirses. annual
confercnLc, unlinc distance-learning COUTSC. member.qhip subscriplions: and .qponsor.%liip. We have also raised money
through the voluntary conlributions of members.
I'olal incoming resources for the year have increased lo £1,217,765 (2023 £1,154,406). This increase has arisen mainly
from the increase in grants to £242,718 {2023 - £120,415).
Donations and legacies have increased in ihe year lo £411,123 {2023 - £255,960). Sponsors of ils annLial conference
symposiums generating funds of £66,000 (2023 - £66,000), and generating annual conference sponsorship income of
£110,5(J) {2023 £90.000). See 'No(e 4 Donations and Legacies" and "Note 6 LncoTne from Charitable Aclivilies" within
the notes lo the financial statements for a detailed breakdown of income received in the year.
Investmen¢ policy #nd objectives
The policy of the BPNA is to invest ils reserves in the further development of ils chariiable aims.
Page 24

British Paediatric Neurology Association
Report of the Tn￿tee$
for the Year Ended 31 March 2024
FINANCIAL REVIEW
The BPNA has also committed reserves lo the sustainability and further developmenl of both the distance learning and short
courses.
As a result of recent financial perfottnanLe, derivcd from additional incoming resources, the currenl level ol" reserves Ihc
BPNA holds cash balances amounting lo £1,053,537 12023 £981.135) and 18 exploring inveslmenl opportuniticb for the
rcscrvcs. Any interest earned will be utilised for re8earLh projccls and othcr aclivilies in line with the BPNA charitsble
objeclivc.%.
Res¢rvcs policy
The tolal funds held at the year end were £963,753 (2023 £932.638) and of which £178.051 12023 £13,076) is
maintained within restricted funds for their delailcd purp05cs as dcscribed in the notes to the financial slaternents. Further
details of reslricied funds are includcd wiihin the notes to the financial siaiement5.
The BPNA implemented two external VAT reviews due lo our large income and making sure we are complianl wilh
HMRC. li has been confirmed that we should have been historically VAT registered and we are now reviewing the cost
implications. This will change the balance of the reserves by next financial year which could be halved.
Overall, the financial position of Ihe charity remains healthy, though the trustees continue lo pay close aiiention lo the mix
of acliviiies in order lo ensure that in trying io achieve 115 objectives it does not lead ￿ deierioralion in the financial stability
of the charity or staff burn out.
A substantial proportion of the reserves in the balance sheet are represented by the cash al bank and in hand totalling
£1,053,537 (2023 £981,135) in order to facilitate the continued activities of the charity by holding highly liquid assets.
The trustees regularly review the finances, budgets, and cash flows to aid effective stewardship of the charity.
The trusiees recognise that the level of reserv¢s fluctuates during periods of inve.4tmenl by the charity and ensure an
adequatc rc5crve is maintained. I'o this end, in 2023-24 the Irustecs increased an unrestricted ¢onlingenLy fund i0 £250.000
(2023 £2(K).(K)O) which is held in order to miligatc the risk of liquidity concerns. The trustees havc agieed the level of
funds held in thi% ￿CLoU￿1 bascd on ihe equivalenl of five monih s Secrctariat salaries plus major overheads including Office
rentals. 'fhi% puliLy 16 rcvicwcd every 12-months.
Fund5 in deficit
Thcrc wcrc no flinds in deficit as al thc financial rcporting date or ihe comparaliye fin&uJcial rcporling dale.
UIURE PLANS
During 2024-25 recruilmenl lo pacdiatric neurology will continue and relationship with other association5 and colleges will
continue lo dcvclop IRCPCH & Association of Briti.sh Neurolngisls).
The BPNA Strategy day will happcn in Scptcrnbcr 2024 in line with th¢ new BPNA President taking up their position which
will inform ihe direction the BPNA should go operationally.
PETI will be launched in Tunisia in November 2024 and in Singapore in early 2025.
PET4ward will laun¢h in April 2024.
The NeoNATE and CHaT courses will undergo a revision in June 2024.
STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
The BPNA is governed by ils consiituiion, approved on 3 December 2014 and updaied at the AGM on 23 January 2019.
Page 25

British Paediatric Neurology Association
Repor¢ of the Tn￿teeS
for the Year Ended 31 March 202A
STRUCTURE, GOVERNANCE AND MANAGEMENT
Melhod of xppointment of trustee5
The management of the Asso¢iaiion 16 the responsibility of ihe trustees who are elected by BPNA meTnbers and appoinled
under the terms of the Consiilulion.
When a new Trustee is appointed a procedure is followed under BPNA policies which includes TrLlStee eligibility
declaration, sending a copy of The Essential TDJStee' guide. Conflicts of Interest policy and Declaration of interest form.
They are also offered training.
Organisational structure and decision-making
The trustees meet four times per year (usually j￿uary. June. September. November) when rn0￿ in depth sirategic decisions
and business matters are discusscd. Monthly Zoom mcctings are also held.
Council is a larger body that mcets twice per year (January and MaylJunc). During 2018-19, Council was expandcd to
include representation from cvery UK paediatric neurology terniary ccntre and the Chairs of ihe Special in(ercst gmups
iogether wilh the representatives ¢o-opied from related organisalions.
The purpose of Council is to ensure a good exchange of inforniaiion and ideas relaied lo the care of children and young
people with neurological conditions and paedialric neurology ediicaiion and training between Centres and other key
organisalions. Please see list of BPNA Council members below:
Page 26

British Paediatric Neurology Association
Report of the Trnstees
for the Year Ended 31 March 2024
STRUCTURE, GOVERNANCE AND MANAGEMENT
Members of BPNA Council Serving During 2023-24
Execulive
President
Sccrelary
Chair, R¢s¢a￿h
Chair. Education Quality & Standards
Chciir, Internalional Education
Direclor, Senior Mallagevnent, BPNA
I'reasurer
l)rofessional Support o￿lcer
National Training Advisor
Name
Dr Ai15a MLLcllan
Dr Danicl Lumsden
Dr Sam Amin
Dr Manali Chilrc
Prof Martin Kirkpatrick
Mr Philip Lcvine
Dr SanLosh Mordekar
Dr Manish Prasad
Dr Dipak Ram
'I'erin F.x
January 2027
January 2025
January 2025
January 2027
January 2025
January 2026
January 2026
January 2027
Pdediali'ic Neui'olo
Belfast
Dundee
Edinburgh
Glasgow
Newcasile-Lipon-Tyne
Liverpool
Manchester
Preston
Leeds
Sheffield
Nottingham
Leicester
Birmingliam
Cambridge
Oxford
Bristol
Cardiff
Ceiiires
I'L.4eiiiaiivL
Dr Donncha Harahan
Dr Alice Jollands
Dr Kenneih Mcwilliam (2nd Term)
Dr Sarah Abernethy
Dr Anna Basu
Dr Rajesh Karuvattil
Dr Siobh&n West
Dr Christian De Goede (2nd Tenn)
Dr Lydia Green
Dr Archana Deskurkar (2nd Term)
Dr Singaravadivelu Velmurugan
Dr Nahin Hussain12nd Terni)
Dr Annapurna Sudarsanam
Dr Deepa Krishnakumar
Dr Sithara Ramda812nd Term)
Dr Andrew Mallick
Dr Johann te Water Naude (2nd ierni)
Dr Gcorgina Bird-LiLbcrman {2nd
Term}
Dr Sanjay Bhate (2nd Tenn)
Dr Naila Ismayilova (2nd Terni)
Dr Sushil Beri (2nd Ternil
Dr Louise H￿lIcY (2nd Term)
J)r Danicl l.um5dcn
Dr Anlonia Clarkc (2nd Term)
Dr Elma Stephen
edr lerm
January 2025
January 2025
January 2025
January 2026
January 2024
January 2027
January 2026
January 2025
Janiiary 2026
January 2025
January 2027
January 2025
January 2027
January 2026
January 2025
January 2027
January 2026
Southampton
JJ)ndun= Grcai Orni<ind Sircei Hospital
London- Chclsca & Wc6tminslcr Hospital
London: Imperial College NFIS Trust
London.. The Rnyal London
London.. Evelina LA)ndon Children's Ho%pilal
London.. Si CFeorge'8 Ho.qpitsl
Abcrdeen
January 2026
January 2025
January 2025
January 2025
January 2025
January 2025
January 2025
January 2027
eci,il Inl¢re%l Cilnu
British Paediatric Epilepsy Group
Cerebrovascular
Children's Headache Network
Feial & Neonaial Neurology
Fetal & Neonatal Neiiiology
The Genetic While Mai*r Disorders
British Paedialric Movement Disorders
Muscle Interest Group
UK Neui'orehabilitation
Chair
Dr Suresh Pujar
Dr Jaspal Singh
Dr Gauiam Ambegaollkar
Dr Anthony Hart (Co-chair 2nd TeThn)
Dr Brigilfr Vollmer (Co-chair)
Dr Rahul Singh
Dr Daniel Lunisden12nd Term)
Dr Tracey Willis {2nd Term)
Dr Peta Sharples (2nd Tei'm)
ear terin
Junc 2025
Febru4iry 2026
January 2025
May 2025
May 2025
January 2025
May 2025
May 2025
April 2024
Page 27

Britlsh Paediatric Neurology Association
Report of the TnLStees
for the Yethr Etmled 31 Moreh 2024
STRUCTURE, GOVERNANCF AND MANAGEMENT
UK-Childhood N¢uro-Inflammatory Disorders
Di Cheryl Hemmingway
Neurocutaneous
Dr Sam Amin (Co-chair)
NeuroLuthncous
Dr Sarah Aylett (Co-chair)
RCPCH SPIN Epilepsy Trainees
Dr Manali Chitre (Chair)
Trainees, Chair
Dr Robert Spaull
Trainees, Depuly Chair
Dr Tom Smith
May 2023
AugLisI 2025
August 2025
Augusi 2025
June 2024
June 2024
Co-o ted
Fditor. DMCN
British Paediatric Ncurosurgical Group
Chair, Neurodisability CSAC
Paediatric Ncuroscienqe% CRG
Neuropqychiatry Rcpresentative
Short Course Development Manager
Distance Learning Development Manager
BPNA 2025 Oxford Organiser
Trainee Rep, Neurodisability
Re.
rL8cnlalive
Dr Bcrnard Dan
Dr Pasquale Gallo
Dr Kaiherine Martin
Dr Anita Dcvlin
Dr Ashley Liew
Dr Colin Diinkley
Dr Louise Hartley
Dr Sandeep Jayawant
Dr James Hammond
Co-opted
Co-opted
Co-opted
Co-oplcd
Co-opted
Co-opted
Co-opled
Janiiary 2025
April 2024
Key management rexnuneration
Total remuneration paid 10 key management personnel during the fjnancial year included wages and galaries amouniing to
£161,792 (2023 - £193,941) and contributiong to defined contribution pension sehemes Df £10,055 (2023 - £9,073).
and 5rn)Lincf<ilion of ke
lana
cmcnt
er8aiinel
Permanent staff have yearly appraisals with aims to achieve for the year and are given opporiunilies to develop themselves
with training that the BPNA covers the cost towards. If siaff achieve all their objectives they will get a grade increase
(between 2qo & 4%) until they reach the lop band of their pay grade.
BPNA staff positions and pay are reviewed annually and are benchmarked within the recrLiiiment market and similar
organisalions.
RE￿ I RENCE AND ADMINISTRA TIVE DETAILS
Registered Charity number
1159115
Principal address
2 Si Andrews Place
Regent's Park
London
NWI 4LB
Trustees
Professor M Kirkpatrick
Dr M J Griffiths
Dr A McLellan
Dr A Parker
DrDRam
Dr S Amin
Dr D Lumsden
Di. M Prasad (appointed May 2023)
Dr S Mordekar
Page 28

rltLsh Paedlatrie Neurology Assoclation
Report o( the Trllstee8
for the Year Ended 31 March 2024
REFERENCE AND ADMif41STRAJIVE DEfAILS
Audl¢or
DonnellyBentl¢y Ltd
70 Chorl¢y New Road
Bolton
BLI 4BY
Bankers
Barclays Bank PLC
15 Bene't Street
Cambridge
CB2 3PZ
TRUSTEES, RESPONSIBILITY STATEMENT
The tru5tee8 are responsible for preparing the Report of the Trustee5 and the financial statements in accordance with
applicable law and United Kingdom Ac¢ounting Standards Iunited Kingdom Generally A¢c¢pted A¢¢ounling Prnctlce)
in¢luding Financial Reporting Standard 102 "The Financial Rep)rting Standard appllcable in the UK ajjd Republic of
Ireland"
The law applicable to charities in Englalld and Wal¢$, the Charities Act 201 l. Chatity (Ac¢oun(s and Reports) Regulations
2008 and the provisions of the trust deed requires the tsustees to prcpan financial statements for ¢a¢h financial year which
give a true and foir view of the stale of affairs of the charily and of the incoming resources and appliealion of rewuw¢s,
including the income and expenditure, of the charlty for that perio¢L In preparing thos¢ financial statem¢nts. lhe Itustees are
required to
select suitthle accounliTrg pollciBs and then apply th¢m consistently.
observe the methods and pi'inciples it) the Charity SORP.,
make judgemen15 and estimatcs that arc r¢asonable and PTudent'
sla¢¢ whether applicable accounting st&ndard8 have been followed. subject to any material departures disclosed and
explain¢d in lh¢ financial statements;
prepaK the financial 8tatements on the going concern b&sis unle85 it is inappropriate to presume d)al thc charlty will
continue in business.
The tnjstees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any tim¢ the
rinan¢ial position of Éhe charity And to enable ihem to cnsurc that the financial statements ¢omply wirli ihe Charities Act
2011, the Charily (A¢¢ounts and Reports) Regulations 2008 ond the provisions of the trust deed. They are also r&S￿nSIble
for safeguardiDg the assets of the charity and heJ)¢e for taking r￿￿onabLe Steps for the pr¢vention and dekction of fraud and
ocher irr¢gu12riti¢S.
Approved by order of the board of trustee8 on
and signed on its behalf by:
r S Mordekar- Trustee
Pag¢ 29

Report of illo Tiideycndeiil Auditor lo the Trtsslees or
Brltlsli Pacdialric Ncutology A8￿￿e1&t]0n
Wc have- audiied Ihe financial .IlaleiMciil8 of Briri.Ili PaLdi&iric Neui'ology A%.iuciaiioii (Ihe 'chJriiy'l for (he year ended
31 Mareli 2024 wliiL,li eoiiipi'i8e the Srui¥inE)71 1)[ FinanLial Aclivilic¥. rlie BalancL sheci, ilic Cash blow Sid(¢ineii¢ and
iintes i(1 IhL fiii4iici&l btaieinenls. inclllding a &uinniaiy of .$igi)ifi¢45I)1￿ccOu￿Ilng iialiLie%. The finuiicial i￿PortI17g framewnrk
Iliat hdg b￿n appliEd in ihttii. prepai'iiiifji) 18 appliLttblv law and UniiL,d Kin&idoiii AL'Luunlin¥ Siaiiddrdi (Uniled KiiikFdum
Cjttncrally Aecepled ALcounling Practice), includiiig PinanLial Re.k)orting .Siandai'd 102 'Th2 Fiiiancial Reporling Siandard
upiilicttble In thc UK Kepuhlie ()[ IrelAnd'.
give 8 (rue and t'gir vi¢w ot Ilie bl?Lie Df the cliariiy's tsflaii'5 a5 81 31 Marcli 2024 and of 115 IIILoming resoiiir¢s and
pplication of ie%ourLeR. I'OT Ih¢ yedr ihen Lnded;
hav¢ been piY)PCTly pi'epared in accoi'diince with Uiiiied Kiiig(l()In GenL'i*lly ALcepied AcLouTiiin¥ Pr￿ctiCe. and
hav¢ b¢en ptttpared iii accnrdfiiiL'e wiLh IhL requiremenii of Ilic Cl)arilib% ACL 2011.
Wc Londucied our &udir in Lccordaiice willi Iniernatioiiul Siai)dards oil Audiilng (UK) IISAS IUT<II Iiid app15¢'abl¢ law. Our
812¢emenf% xeciion of oui. I'eport. W¢ are iiidcpendEni of Ille ¢lidriiy in aLeoi'daii¢e willi Ilie eLhical ir<iuiirmeni.s ihal are
r¢lev8ni to our audii of rlie finaiiciLI .%ioi¢iMent5 iii LhL UK, iiiclu(ling Llic F,'RC.'s EI111Cic I ,%lindard, aiid we liovo fulfilled nui.
Iiti. EIIIiLiil I'eSFK)nbibiliiie& in ilCLtJi-dtincg wilh the￿ts I'eqklll'ements. We believe Iliai IliL diidit evid8n¢e wo liuve ()htilll)ed
Culi¢lusioi￿ relallrhg lo Kolhg ctsiice111
In iudiLin¥ Ihe fii)anLial ilaLcin¢nLI, wtt liavL ¥onLliided ihai th# Iru%leLS' U%L <)[ guiiiLI LL)IlLerri bag18 of aLLOlliiLSiig iii Lhe
prepar&iion uf th¥ fii)&llLial &lui#in#iiis is approprillle.
BaNcd on ¢liL WOTk wc Iinve p¢i'l'oi'nicd, Ivc havc iiot idciiiilicd any ii?a(crial uiicer(aiiili&% I'clalill&) IL> LVel)i% or LOTSdiliun.
that. individiiRlly nr coll¢ciivcly. Iiiay CiiSI %igiiil'l¢iinl iJoiib( un Ilie Lli4rily'S abiliiy 10 coiiiii)Iic as a going concern for
Oui. re5ponsibiliiies and 1118 respuiisibilities ol. Ihe Ii'iist¢c¥ wiih respeLi [() going c011eern arc d¢bcribed in Lhc relevan(
seclions iyc thL5 repoit,
Oilier Infnrillatiun
Tlie trusices are reai?i?Tl.%ihltt ffjr the nihoi, iiiftsriiiotion. Tli¢ oihLr inloriiiatiiin ¢oiiipriscs Ihc iiil'orination included iii ihe
Slti(cd iii our iei7(JTI, we dLi Iini cxiirL%.4 iiiiy I'orni ol kl.s6uraiiLY C()IILlu,%iuii ￿l¢ll0￿.
Tn coiiiieciioi) witli ODI. audil o( (hc liiiBnL'ial slalttnienis, our respi)n.sibilily [.% 10 rcad Ilic aiher iTiforrralian ai¥J. in doijg $0,
eonsidor whLbrliei tfjie oiliei. infui'iiiiiLinii 1% rnaierially incoiisis￿n1 wilh Ihc finaiicial siHiemenlS oi. our knowledge obLaiiicd in
Ihc audil f)I' otlierwise &ppears 10 bc nialLI'i#lly mi.%Sl#lcd. Ir we idcntify .%uch Inaicrial incoii%i%iciici¢.4 oi. appaiiiit maierial
I￿ issiul¢snenis, wtt ure rcqLiired to dLierrnine ivhEilieY Il)is ¥ive,% rile 10 a mdleriol iiii55iaieintnl iii thc fiiiènLial Sta￿nien[S
thcnistlves. Ir. b￿SLd an Ili¢ woik we Ii>vc PLrfLirmL,d. WL ¢()￿c1LldC 11141 IhLre is a InalLI'ial Iiiisyialemtiil of Lhis o(liei'
iiif(*mKtion. we r¢qi(iied ¢0 reiioi't Iliiii fklcl. We hiive Iiuihing to repori in Iliix ii'.giii'd.

Report of the Ind¢pendciit Auditfir to the Thistees of
Brilisli Paedlatric Neurology As%oclAtlon
Malters on wliieli we are requlred to i*port by exception
We have noihin¥ lo reporl 111 TespeLt of Ihe lollowiiig maiicr.% whei'c Ihe ChariLi¢s {Ac¢ounls and Reports) Regul¥tioiis 2008
reqiiiffs us io ycptsrr to you if, in oui. opiiiion=
the infnrmatioii given in ihe Report of Ilie Trnstecb is inconxistent in any mdiei-ial I'Gspect with Ihc financial .%tatcments;
or
sufficieni accounting rocords havc not been kepi- or
tlie finaneial statttmenis are n()t in agi'eelncni with die accuuniing recnrds and rellir￿. or
we have nul reLeivLd all (hL inforinttiion and txplana(ions we require for vui. aLidii.
Responsibilities of trustees
As explained mor¢ fully in lh¢ Tru8te&%' Re8pi)nsil)ilitie% Statement, Ihe li.￿$(¢e% arc rc5POD.%ihle for the prep3ratioD of the
fiiianLial starements and loi. being $ati%fi¢d that (h¢y give a irue &nd fair view, and for liucl) internal Lonirol as the trnsiees
de[Cr￿)In¢ i¥ iiecebsai'y w enable (lle preparaiion of fiiiancial Staiements tliat are free froin malerial niis.%iateinent, wlieiher
di1¢ to ti'aLid oi. ciyor.
In pi'epariiig rli¢ financial bl4iLemeiits. the trus(¢¢5 are responsible for assessing tli¢ charity's abilily t(J continlle as a going
conceni. disLlo%ing. ds applicablc, Inattcrs related ro goiiig concei'n and using dic going CDI)cern bdSit> of accounting unlc$6
the tTiislees either iiilend 10 liquidate Il)c cl)aTity or to cease operaiKons. or have no reali,sric altei'native but lo do.$0.
Our responsibilities for the audll of the Iln•knclal stateinents
We have been appointed a8 auditor under SeL"(ion 144 fif Ihe Chariiies Aci 2011 and repDrt in accordance with the Ae¢ and
relevant regullltsons Inade or having effe¢1 th¢reuiid¢r.
Our objeLLives are (o obiain veasonable a$su17nLe aboui wliL(hci' lh¢ fiiianoi81 %ialements aq & whole arL firL. froni malerial
missiateni¢nt, whethei. due to fraud or errnr, and io issue an auditor's repori thai iiicludcs our opinioii. Reasonable &5burance
is a high level nf assuranc¢: bu¢ ili n()t a guarantee Ili&t dn audit coiiductLd in accordai)ce with l.SAs (UK) will Rlways detec(
a material niis%ia(LinttllL wlittn il e%isis. Mi58iaiemenis ¢an arise frum fralld or error and arL¥ Ly)n8idered m&tLrial ir.
individually or in tile aggreuaie, (hey could reasonably be expected to influencL tl)e economic dccisions of u.sers takeii on
the basis of ihe* fiiiaiicial bt&teinents.
Irregularitie5, iiicluding fraud, ar¢ in51anccs of non-coinplianee witli laws and Legulaiions. We design pro¢edures in line
witli our I'esponsibilities. outlined above, lo detec[ material missiatemenis in r&¥peeL of irr¢gulai'i(ie¥, including fi'aud. The
c%(eni 10 wliich our proccdllre5 arc capablc ol dcteciing iffcgulariiics. incliiding fraud is dctail¢d bclow..
We obtained an understanding of the legal and regulatory frainework applicable tu the cliari(y aiid the sector in whicli il
QPLY'aies and Lnnsidercd ihe risk of non- compliance with ai?pltulile IdW.S oi. regiilalinns.
We detennined that ilie followiiig laws aiid regulations were Inosl significant: the Charili¢s Act ?01 l and Accounting and
Rei)()rtsiig hy Chariiies.. ,8iatenwnt ()f Recommended Praclice Api)licable to cliarities preiwring tlieir aCLOLlli16 in accordance
wilh the PinanLial RLponing Stsndai'd appliLable in thL UK and RttpubliL of Ii'eland is.%lled in OL'¢uber 2UI g. W¢ designed
audii proL'edure8 to respond to rhc risk. recognizing 11)at tlie risk of not deiec(ii)o a material misslatement dlle to fraiid is
highcr Ilian thc risk ()[ lio( delec(ing one rcbultiiig froin error. 85 fraud mily involve deliberate coiicealmenl. for example,
rorgery or illtcntiunal 1￿1.5repre.1tl)la(Itsns, or ihruugh Lollusii)n.
We obiained an und¥i'blandiiig of how Ihe LI1￿)LY ib complyiiig will) thosv le8￿ and regulaiory fraineworks by making
cnqllii-i&% of thu rnana¥cnicni. We coi'roboi'a¢ed our cnquirie.s through our rcviLw of board Ininut&%.
Oiir tests also included ag￿¢11]g the financial Sfdteinenis disclo.%vreb to underlyino SUPPOTtiiig documentation. There are
inhcreht limitation& in (hc dudii pi'occthirc& dcscribcd above ai)d. th¢ I'iii'lhci rcmoved noii-cornpliancc with Idws and
I'egulaiion,% froni tlie events and iraii8actLOII8 reflectod in tlic financial .%iaienienLS. the less likely we wnuld become aware
uf it. We did not identify aTJy key audii Matters r¢lalin8 (o irregul￿7(1¢5, incllldiiig fraud.
WL al%LI ddre%fe(i ihtt ri.sk of Thaoageinenl ovenide of intwnal LQ)nirol&, inelllding lesling joui'na15 and evalualing wheiliey
there was evidence of bias by the direciors tliat I'epresenled a risk of Inaierial mi8sLatemeni due 10 fraud.
Page31

Report oethe tndependent Auditor to the Trustees or
Britlsh PaediatrAC Neurology Association
A further description of our responsibiliiie* for ilie audii of the fsnancial staieineiiL%' is located on the Finaiicial Reprjriing
Council's websiitt a( www.frc.org.uklaudiiorsresponsibiliiies. This descripiion forins parl of our Repori of the Independent
Audilor.
Use of our report
Thib Irporr 18 made solely to the chariry's Irus¢ees. a¥ & hody, in accordance wilh P&rL 4 of ihe Charitics (AcL'Dunts' and
Repoi'ts) Regulation8 2IX)8. Ollr alldiL work lia% been uThderraken so iba( we mighi sta(e 10 the chariiy's Lrusrees those matte13
we requir¢d to state to ihem iii an auditor's Jtporl and for iJo otlier purpose. To rhe fullesi ¢xceDI penniLted by law. we do
not ac￿p1 <Jr J&&urne responsibilily 10 dnyane oiher than the eharily and ihe charily'b lrnstees is a body. for nur audit work.
foi. Ihi8 rcporL, or for (lie opinions WL have formed.
D..4Ert
LVJ
DonnellyBeniley Ltd
70 ChorlLy N¢w Road
Bolton
BLI 4BY
Daio:
DonnellyBeniley Lid i& eligible for 4ppoiiiiment as auditor of the charity hy virtue of its trligihility for appoilllment
audiror of a c(ITnpany under secuun l ?12 of the Companies Aci 2006.
Page 32

British Paedlatrlc Neurology Associ8tion
Statement of FinAnclal Actlvities
ror the Year Ended 31 March 202A
2024
To￿1
funds
2023
Total
funds
Unrestricted
fundg
Restricted
Noles
INLC)ME AND FNDOWMENTS FROM
Donations and legacies
150.001
261,122
411.123
255,960
Charltable gctlvities
Annual confcrence
Shurt courses
Distance learning courses
International shorL courses
R¢s¢arLh
Membership and professional support
IPNS recharges
Confcrcnccs, courses and recharges
Professional support
Suppon co8tS
Invited Rcvicws
Inveslment income
294.950
288.591
67.281
3.469
1.2tK)
117,784
294,950
2811,591
67,281
3.469
1,200
117.784
344,377
268,917
71,560
31.156
1.200
109,963
43.728
11,670
5,499
3,BlO
11,670
5,499
3,810
5.304
19,4(K)
2,841
12,388
12.388
Total
956,643
261,122
1,217,765
1,154,406
EXPENDITURE or4
Charitable activities
Annual conference
Short courses
Distance learning courses
International short courses
Research
Membership and professional support
EPNS recharges
Support costs
Governance costs
Invited Reviews
338.310
148,967
96.Y72
184.219
105.449
135,500
338.310
260,287
96,972
184,219
105,449
135,5(NJ
211,318
205.950
89.960
176,789
105,503
123,614
40,490
9,811
47,441
20,284
111,320
11,224
43.918
10.771
11,224
43,918
10.771
Total
1,075,330
111.320
1 186 650
1,031.160
NET INCOMEI(EXPENDITURE)
Transfers between funds
(118.687)
{15.173)
149,802
15,173
31.115
123.246
17
Net movement in Cunds
(133,860)
164,975
31,115
123,246
RECONCILIA TION OF FUNDS
Tothl funds brought forward
919,562
13,076
932.638
809,392
The notes form part of these financial statement5
Page 33

British Paedlatrlc Neurology Assoclatlon
Sta¢¢ment of ￿nancIAl Activities
for the Ye8r Ended 31 MArch 2024
2024
Total
funds
2023
Total
funds
Unrestricted
funds
Restricted
funds
Notes
TOTAL FUNDS CARRIED FORWARD
78fj,702
178,0f1
9()3,753
93?.6.18
CONTINUING OPERATIONS
All inwme and expenditure has arisen from continuing activities.
RKSTRICfED INCOME AND EXPENDITURE
Comparatives for income and expenditure
All income and expenditure in 2023 was unrestricted apart from:
Donations and legacles Income
International League Against Epilepsy (ILAE)
The Buist Fund- University of Dundee
Jazz Pharn
65,915
20,000
12,000
Charitable 4c¢lvltles expenditure
Short ¢ours¢s
International short courses
Annual conference
Membership and professional support
Research
Invited Reviews
Distance learning courses
Governance costs
14.281
36,877
8.395
8.160
2,352
970
9,442
4.362
The notes form parl of these fjnancial sialements
Pag¢ 34

Brltlsh Paedlatrlc N¢urology Asso¢i4tion
Balance She¢É
31 March 2024
2024
Tota]
fvnds
2023
Total
funds
Unrestri¢led
fi]nds
Restricted
fuAd8
Notes
FIXED ASSEYS
Taugibl¢ assets
12
21.243
21.243
10.402
CURREwf ASSETS
Stocks
Debtors
Cash at bank ond in hand
13
14
9.023
55.087
885.602
9.023
65,203
1.053,537
11,061
40,051
981135
10,116
167.935
949,712
178,051
1,127,763
1.032247
Amounfs falling du¢ within one yadr
15
1185253)
(185.253)
Iiio,oii)
ET CURRENf ASSETS
764,459
178,051
942,510
922236
TOTAL AsS￿s LESS CURRENT
LtABtLITIES
785.702
178.051
963,753
931638
NET A&8ETS
785.702
179,051
963.753
932,618
FUNDS
17
Urtrestricted funds
Re$(ricted ￿lldS
785,702
178051
919562
13,076
TOTAL FUNDS
963,753
932.638
11 tu...
The financial sraternents were approved by Ehe Board of T￿￿tee8 and auth0ri5ed for issue on ......................................
and were signed on its beb8]f by..
Dr S Mordekar-
The notes forni part of these financial statements
Page 35

BHtlgh Paedlatrle Neurology Asso¢latlon
Cosh Flow Sthtemenl
(or tli¢ Year Ended 31 Mgr¢h 3024
2024
2023
Noi¢s
Cgsh flow8 from operntlll8 actlvliles
Cash ￿n￿Oi.ed from operall￿]
711.-5118
c8¥h proylded by operating activities
78,.fi68
Coth now8 from Inveitln¥ acllvltle
PurohoNe ts( Langible fixE(J
Sal¢ of tangible flxed ￿$8[5
Intere6tn¥iv¢d
(l8.61U)
(4.LJ(}lJl
,1141
Net eaxh uBed In Inv¢8ting activities
1.1.1281.
Clignge In c8¥h ewsh equlvslenls In the
r¢portlTrg perlod
C#6b and cAs1i equfvalents at the he￿nnIng
of thoreporthig yerlod
72,402
872,fJQfi
Cath 4nd ￿5h equlvglents at the end of the
reportlmz perlod
1,0.53,-fj.?7
981 115
The nolES form parl of Ili2se finaiicial S￿remen[S
Po¥¢ 36

Brlilsh Paediatric Neurology Association
Notes to the Cash Flow Statement
for the Year Ended 31 March 2024
RLCUNCILIA TION OF NET INCOMF "ro NET CASH FLOW FROM OPERATIIYG ALryIVITIES
2024
2023
Net income for the reportlng period (As per the Statement of Financial
Activities)
Adjustments for:
Depreciation charges
IA)ss on disposal of fixed assets
Inieresi received
Decrease in stocks
Increase in debtors
Increasel(decrease) in creditors
31.115
123,246
7,081
652
(12,388)
2,038
125,152)
75,242
3,470
{2,841}
4,623
(3,118)
(13,812)
Net cash provided by operations
78,588
111.568
ANALYStS OF CHANGES IN NET FUNDS
At 114123
Cash flow
At 3113124
Net ea5h
Cash at bank and in hand
981,135
72,402
1,053,537
981,135
72,402
,053,537
Total
981.135
72.402
,053,537
The notes form part of these financial statements
Page 37

British Paediatric Neurology Assoeiation
Notes to the Financial Slatements
for the Year Ended 31 Mgreh 2024
STATirroRY INFORMATION
British Paediatric Neurology Associalion is a charitable incorporated organisation registered with the Charity
Commission for England and Wales. The registered charity number number is 1159115 and the principal address is
2 St Andrews Place, Regents Park, London, NWI 4LB.
The charitable incorporated organisation constiluies a PLiblic benefit entity as defined by FRS 102.
The presentation currency of the finE￿¢￿al 8taiemenis is the Pound Sterling (£).
ACCOUNTING POLICIES
Basis of preparing the fin&nci41 statements
The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in
accordance with the Charities SORP (FRS 102) 'Accour]ting and Reporting by Charities: Siaiemenl of
Recommended Practice applicable lo charities prepai'ing their accounis in accordance with the Financial Repor(ing
Standard applicable in the UK and Republic of Ireland (FRS 102) (effective l January 20191,, Financial Reporting
Standard 102 'The Financial Reporting Siandard applicable in the UK and Republic of Ireland, and the Charities Act
201 l. The financial slalemenls have been prepared linder the historical cost convention.
Going concern
The Trustees have assessed wheiher the iise of the going concern basis is appropriate and have considered possible
events or conditions that might cast significant doubt on the abiliiy of the charity to continue as a going concem.
The Iruslees have made this assessmeni for a period of at least one year from the date of approval of the financial
siatements. In particular the trustees have considered the charities forecasts and projeciions and have taken aCCOLint
of pressLires on income. After making enquiries ihe iruslees have concluded thai there is a reasonable expectation
that the Charity has adeqLlate re8ources to coniinue in operation1< l eXiS￿nCe for the foreseeable fLilure.
As such ihe charity can expect lo be able to meet ils liabilities as they fall due in the period of al least 12 monlhs
from the dale of approval of these accounts. However, there can be no certainty in relation to these matters.
On this basis the Trustees have concluded that the charity is a going concern. The financial statements do not
include any adjustments that would resiilt from the charity noi being able lo meet ils liabilities as they fall due.
Income
All income is recognised in the Statement of Financial A¢tivilies once the charity has enliilement to the funds, it is
probable that the income will be received and the amolinl can be measured reliably.
Income from grants and donatlons
Donaiions and grants are recognised when they have been commiini¢aled and received in writing with notificaiion
of both tFLe amount and settlement da￿. In the evenl tha( a donation or grant is subject to conditions ihal requii'e
level of performance before the charity is entitled to the funds, the income is defei-red and not recognised until either
those conditions are fully met. or the fulfilment of those conditions is wholly within the control of the charity and it
is probable that those conditions will be fulfilled in the reporting period.
Ineome from membership subserlptions
Membership subseriplions are initially recognised in the period that the member pays the subscription ￿ the charity.
Membership SLibscriplions received in the year relating to the period after the reporiing date are re¢ognised as
deferred income.
Income from sponsorship ggreements
Page 38
coniinued..

British Paediatric Neurology Association
Notes to the Flnanclal Statements - continued
for the Year Ended 31 March 2024
AccouwfING POLICIES - eontinued
Income
Sponsorship income is initially recognised when invoiced in line with the terms of the sponsorship agreement.
Income received or invoiced in the year relating to the period after the reporting date are recognised as deferred
income.
Income from conferences
Income in relalion lo conlercnccs is inilially recognibcd in thc period in which the atlendee pays Ihe allendance fee.
Income received for conferences taking place after Ihe rcwrling date are recogni.4ed as deferred income.
Income Crom courses
Income in rclation to courses is initi<illy recognised at the point which the attendee has booked and paid for iheir
attendance on the coursc. Incom¢ received for courses laking place after the rcporling dale are recognised a5
deferred incotne.
Income from EPNS recharges
Income in relation lo EPNS recharges is initially recognised ai the point which the EPNS is invoiced for the costs
incurred by BPNA. Inconie not invoiced a5 at the reporting date is recognised as accrued income within the fJnan¢ial
statements.
Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or conslruclive obligation committing the charity
to Ihat expenditure, it is probable that a Iransfer of economic benefils will be required in settlement and the amount
of ihe obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified
under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular
headings they have been allocated lo a¢livities on a basis consisienl with the use of resources.
Grants offered subject lo conditions which have not been met at the balance sheei dak are noled as a commitment
bul not accrued as.expendilure.
Tangible fixed a55ets
Deprelialiun is pruvided ai the following annual raies in order to Wri￿ off each asset over its estimaled useful life.
Plant and machinrry
Fixturcs and fillings
25% on rcducing balance
25% on rcducing balance
The tangiblc fixed assels of the charity are reviewed by the charity's executive director and ihe trustees for
impairmenl on a regular basis and during the preparation of the financial staiemcnls.
Stock5
Siocks are valued at the lowcr uf cobi and Det rcalisablc valuc, aficr making due allowancc foi obbolele and slow
moving ilem8.
Taxation
The chariiy is exempl from lax on ils charitable activitie5.
Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives al the discretion of Ihe Irustees.
Restricted fund5 can only be used for particular restricted purposes wiLhin the objects of the charity. Re51riclions
arise when specified by the donor or when funds are raised for particular restricted purposes.
Page 39
continued...

Bri¢ish Paediatrlc Neurology Assoelation
No¢es to the FI￿ncial Statements - continued
for the Year Ended 31 Mareh 2024
ACCOUNTING POLICIES - contlnued
Fund accountlng
Further explanation of the naiure and purpose of each fund is included in the noies to ihe financial slaiements.
Debtors and credltors receivable I payable within one year
Debtors and creditors with no stated ini¢rest rate and receivable I payable within one year are recorded at transaciion
price. Any losses arising from impairment are recognised in expenditure.
Forelgn eurrencies
Asseis and liabilities in foreign currencies are translated into sterling at the rates of ex¢hange ruling at the balance
sheet date. Transaciioiis in foreign ¢iirrencies are translated inio sterling at the rale of exchange ruling at ihe dale of
transaction. Exchange differences are taken into account in arriving at the operating result.
Pension costs and other post-retirement benefits
The cliarity operates a defined contribution pension scheme. Contribuiions payable to the charity's pension scheme
are charged lo the Statement of Financial Activities in the period to which they relate.
Flnoncial instruments
A financial assei or a financial liability is recognised only when the eniily becomes a pariy lo the conlraclual
provisions of the insiruments.
Basic financial instruments are initially recognised ai the transaction price, unless the arrangemenl constitutes. in
effect, a financing transaction, where il is recognised at the present value of the future paymenis digcoiinled al a
market rate of interesi for a similar debi iustrument.
Debt instrumenis are subsequently measured at amortlsed cosi.
Other financial instruments are initially recognised at fair value, unless payment for an asset is deferred beyond
normal business tern)s or financed at a rale of interest thal is not a market rate, in which case Ihe asset is measured al
Ihe pi'esenl value of the future payments discounted at a market rate of inleresi for a similar debi instrument.
Financial assets that are measured at cost or amortised cost are reviewed for objecrive evidence of impairment at the
end of each r¢porting date. If there is objective evidence of impairment, an impairmeni loss is recognised in profit or
loss immediately.
Any reversals of impairnieni are recognised in profit or loss immediately, io the extent that the reversal does not
result in a carrying amounl of ihe financial asset ihat exceeds what the carrying amount would have been had the
impairmeni not previously been recognised.
Page 40
conlinued.-

British Paediatric Neurology Assoel8tlon
Notes to the Flnanclal Statements - continued
for the Year Ended 31 March 2024
CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION
UNCERTAINTY
The preparation of the financial statements requires managemenl to make judgements, estimates and assumptions
thai affect ihe amouiits reported for asset5 and liabilities as at the balance sheet date and the amounts reported for
revenues and expenses during the year. The nature of estimation means that actual outcomes may however differ
from ihose original eslimales.
The trustees do not deem there to be any judgements. apart from those otherwise disclosed in the accounting
policies or notes to the financial stalemenls, which require highlighting to the readers as a result of having had a
Critical effeLI on amounts reeognised in the financial slalemenls.
DONATIONS AND LEGACIES
2024
2023
Donations
GranLs
Gift aid
Membership donalinns
Annual cnnferencL Sponsorship
Short course sponsorship
Trainee Sponsorship
Misccllancous income
23,660
242,718
5.245
120,415
1.063
1,950
90.0(K)
25,5
11,200
110.500
14,750
7,500
795
.787
411 123
255,960
Grant5 received, included in the above, are as follows-
2024
2023
Inlernaiional League Against Epilepsy (ILAE)
Department for International Development (DFID) via the Tropical Health
and Education TrL151 (THET)
Pet Grant
Movement di50rder income
The Buist Fund- University of Dundee
GW l Ja7.7. Pharma
BAND & RUW Foundations Grant
54,878
156,300
65,915
5,(M)O
15.000
7,500
2O,OUO
12,OLK)
26.540
242,718
120,415
Page41
continued...

Bri¢ish Pv4ediatric Neurology As80¢iation
Notes to the Fhnanelal Statements . contlnued
for the Year Ended 31 March 2024
Sponsorships received, included in the above, are as follows:
Conference
sponsorshlp
Course
sponsorship
2024
Tota18
2023
Totals
Company name
Alexion
BioGodex
Biogcn
D¢silin
Egetis
GWlJaLz Pharnia
Neuraxphami UK
Immedica
Novartis
Nutricia
Orchard
Orion Pharnia
Proveca
prc
Roche
Sarepia
UCB Pharma
Veriton
Vitaflo
6,0
7,5(K)
7.5(Kl
6.0(K)
6,OtM)
6,000
7,500
7.5(M)
19,750
6,0(Y)
9.0(M)
6.0(K)
20,5(K>
6.(K)O
13.750
9,000
6,0
6,000
2,000
7.500
6.000
7,5
6.000
2,000
7500
6,000
7,500
6,0
6,0
6,0
6,0(K)
2.0(K)
6,0(M)
7,500
7,500
13,5(K)
6.000
6.(K)O
2,0
6,0
8,5CH)
7.5tK)
13,5(K)
6,(M)O
6.LK)O
I,(K)O
8,(X)O
9.(M)O
6.(K)O
To¢al Sponsorship
110,500
14,750
125,250
115,500
Pag¢ 42
continued...

British P8ediatric Neurology Association
Notes to the Financial Statements . contlnued
for the Year Ended 31 March 2024
INVESTMENT INCOME
2024
2023
Deposit account interest
12.388
2,841
INCOME FROM CHARITABLE ACTIVITIES
Distance
learning
cour5CS
Annual
conference
Shor(
courses
Annual confeicnce
Short courqes
Intemational short courses
Distance learning
EPNS rechargeb
BPNSU fee income
Invited Reviews
Trainee Fees
BPNA membership subscriptions
Annual conference symposium sponsorship
External room hire
228.950
288,591
67,281
66,000
294,950
288,591
67,281
Page 43
continued...

British Paediatric Neurology Associatlon
Notes ¢0 the Financlal Sts¢ements- COn￿￿lled
for the Year Ended 31 March 2024
INCOME FROM CHARITABLE ACTivrrIES - continued
Membership
Conferences,
courses
and
recharges
International
short
courses
professional
support
Research
Annual conference
Short courses
International short courses
Distance learning
EPNS reCh￿geS
BPNSU fee income
IDVited Reviews
Trainee Fees
BPNA membership subscriptions
Annual wnference symposium sponsorship
Bxlernal r(K)m hire
11,670
3.469
1,200
117,784
3,469
1,2(X)
117.784
11,670
2024
Total
activi¢ies
2023
Total
activities
Professional
support
Support
¢osls
Annual conference
Short courses
Inlernalional short courses
Distance learning
EPNS recharges
BPNSU fee Income
Invited Reviews
Train¢¢ Fees
BPNA membership subscriptions
Annual conference symposium sponsorship
ExlernaI room hire
2,460
243,080
288,591
3,469
67.281
278.377
268,917
31,156
71,560
43,728
1,2(Kl
19,4(K)
5,304
109,963
66,000
1,2(X)
5,499
5,499
117,784
66,(KJO
350
1,3.50
7()4,254
8().5.605
Page 44
coniinued...

Brltish Paediatric Neurology Association
Notes to the FiJJancio1 Statements - continued
for the Yegr Ended 31 March 2024
Sponsorships received. included in the above, are as follow5-
Symposia
sponsorship
2024
Totals
2023
Totals
Company name
Biocodex
Biogen
Desiiin
GWlJazz Pharma
LTF Pharnia
Novartis
Frc
Roche
UCB Pharma
Total Sponsorshlp
I 1,000
11,000
LI,￿0
I l.O(K)
I I,O(K)
I I,O(K)
I 1,000
11.000
I 1,000
I 1,000
I I.OQK)
I i.o(K)
I I.ooM)
I I,o(K)
I I,(K)O
I i.(M)o
66,000
i i,o(x)
i i.o(MJ
66,000
66,000
CHARITABLE ACTIVITIES COSTS
Grant
Grant
funding of
aclivities
(see note
81
Support
costs (see
note 9)
Direct
Costs
Totals
Annual conference
Short courses
Distance learning courses
Inlernaiional short courses
Research
Membership and professional support
Support costs
Governance costs
Inviled Reviews
240,731
110,4(K)
30,548
59,885
4,034
76,786
11.224
97.579
149,887
66,424
124,334
18,446
58,714
338,310
260,287
96,972
184,219
105,449
135,5(K)
1.224
43.918
10,771
82,969
43,918
10,771
533,608
82.969
570,073
1,186.650
Page 45
continued...

Britlsh Paedlatrlc Neurology Assocl8tJon
Notes to the Financial Statements- Continued
for the Year Ended 31 March 202A
GRANTS PAYABLE
2024
2023
Research
The total grants paid to institutions during the year wa$ as follows:
2024
2023
Year l of 3 joint research training fellowship with Action Medical Research
Year 2 of 3 joint research training fellowship with Action Medical Research
Year 3 of 3 joint research training fellowship with Action Medical R￿arCh
41.667
41.302
41.667
41.302
82.y6()
Page 46
ontinued...

Brittsh Paediatric Neurology Association
Notes to the Financial Statements . conlinued
for the Year Ended 31 March 2024
SUPPORT COSTS
Infomation
technology
Human
resources
Finance
Annual conference
Short courses
Distance learning courses
Intemalionul %horl courses
Research
Membership and profc$￿ional sllPPOrt
Governance co81
Invited reviews
113
174
78
145
22
69
38
4,423
6,796
3.1112
5.637
836
2,662
1,458
488
73.767
13,314
50,219
93,997
13.946
44,387
24,309
8,142
652
25.312
422,081
Governance
cost5
Other
Totals
Annual conference
Shorl courses
Distance learning courses
Intemational short cour5e5
Research
Membership and professional sUPPOrt
Governance cosls
Invited reviews
18,540
28,474
12.615
23,619
3,504
11,154
6,108
2,047
736
1,129
500
936
138
442
12,005
81
97,579
149,887
66,424
124,334
18,H6
58,714
43.918
10,771
106,061
570 073
Support costs, included in the above, are as follows..
Distance
learning
courses
International
short
COLifscs
Annual
conlLrLnLe
Short
courses
Research
TrustCCs' remuneration elc
Loys on sale of tangible
rixed dsscls
Safiware subscription
Computer repairs
Wcb5ilc h05ting
Website development
Computer upgrade
Dcpreciation of tangible
fixed assets
Employmenl costs
Social security
Pensions
113
1.651
259
95
1,157
51
174
2,536
399
145
1,779
76
78
1.124
177
64
788
34
145
2,104
331
120
1.475
63
22
312
49
18
219
1,210
61,803
5.223
3,679
,861
94,934
8,024
5,651
825
42,073
3,556
2,505
1,544
78,750
229
11,684
987
696
4,689
Carried forward
75,241
115.579
51.224
95,877
14,2
Page 47
continued...

British Paediatric Neurology Association
Notes to the Flnand&l Ststenients- contlnued
for the Year Ended 31 Mareh 2024
SUPPORT COSTS - continued
Distance
earning
courses
International
short
¢ourses
Annual
conferenc¢
Short
courses
Research
Br()ugh¢ fonvard
Sthff costs
Staff trnining & Welfare
Recmitment costs
Business rates
Gas and electric
Telephone
Office insurance
Data protection costs
Health and safely ￿sts
Legal fees
.Marketing
O￿lCe repairs and renewals
Photocopier
Postag¢
PrAnting and sialionery
Credit card charges
Bank charges
Bad debi
Refuse and cleaning
Computer and internet
Staff welfare
Copyright lic¢nce
London r¢nl
Bolton rent
Meeting costs
Professional fees
Depreciation of tangible
fixed assets
Audilors, remuneration
Ac¢ounlan¢y and legal fees
75.241
396
2,314
352
35
42
713
400
42
115,579
609
3,554
542
52
51,224
270
1.575
240
23
29
485
272
28
95.877
505
2,948
449
43
55
908
510
53
14.225
75
437
67
1,095
615
64
135
76
744
2,919
107
23
,l42
4,483
163
35
506
1,987
72
15
947
3,719
135
28
141
552
20
167
1,568
179
256
2.406
276
118)
13
242
1,357
196
10,071
2,700
585
2,633
113
1,066
122
(8)
212
1.996
229
(15)
31
296
34
(2)
157
883
127
6.556
1.758
382
1,714
107
201
1.126
163
8.354
2.239
486
2,184
30
167
24
1.239
332
72
324
87
4.463
1,196
259
1,167
26
315
421
40
483
646
18
214
286
33
401
535
59
79
97,579
149.887
124.-334
18.44C)
Page 48
niinued...

British Paediatrlc Neurology Association
Notes ¢0 the Financial Sta¢ements- continued
ror the Year Ended 31 March 2024
SUPPORT COSTS - continued
2024
2023
Membership
and
profcssional
siipport
Governance
costs
Invited
Rcvicws
Total
activities
Total
activities
Trustees, remuneration etc
Iffjs5 on sale of iangible
fixed assets
Software %ub8cription5
Computer repairs
Wcbsite hosting
Website developmcnt
Compulcr upgrades
Depre¢i8tion of tsngible
fixed aqsets
Bmploymenl cos15
Social security
Pensions
Staff costs
Staff training & welfare
Recruitmenl costs
Businegs rates
Gas and electric
Telephone
Office insurance
Data protection costs
Health and safety costs
Legal fees
Marketing
Office repairs and renewals
Photocopier
Poslagc
Printing and slatiunery
Credit card Charges
Bank charges
Bud dcbt
Rcfusc and cleaning
Computer and inlerncl
Staff welfare
Copyright liccnce
London rcnl
Bolton rcnt
Meeting Costs
Profes.8ional fees
Depreciation of langible
rixed assels
8,122
69
99_3
156
57
697
30
38
544
86
31
382
16
13
182
29
10
128
652
9.446
1,486
540
6.625
284
7,416
712
576
2,400
729
37,187
3,143
2,214
239
1,392
212
21
26
429
399
20,366
1,721
1,213
131
762
134
6.821
577
406
6.931
353,618
29,887
21.053
2.269
13.237
2.017
195
245
4,079
2,290
239
3.261
302.331
27,275
15,155
11,170
1,183
9,873
374
255
39
14
235
132
14
79
5,197
1,279
239
25
M7
1.756
64
13
245
962
35
82
322
12
4,254
16,700
608
127
3,161
3,521
(125)
115
395
940
10.604
955
157
100
943
108
(7)
55
516
59
(4)
18
173
20
952
8.964
1,027
{66)
48
901
5,055
730
37,512
10,055
2.181
9,807
95
532
77
3,945
,057
229
1,031
52
291
42
2,160
579
126
565
17
98
14
724
194
42
189
730
40,638
9,0(K)
16
150
Carried forward
58,272
31,913
10,690
554,106
466,863
Page 49
continued..

Brilish Paediatric Neurology As50Cj4tion
Notes to th¢ Financial Statements - contlnued
for the Year Ended 31 March 2024
SUPPORT COSTS - continued
2024
2023
Membership
and
professional
suppon
Governance
costs
Invited
Reviews
Total
activities
Total
activities
Brought forward
Auditors, remuncration
Accountancy and legal fees
58,272
189
253
31,913
9,104
2.901
10,690
35
46
554,106
10,800
5,167
466,863
9,(K)O
8,369
58,714
43.918
10,771
570,073
484,232
io.
TRUSTEES. REMUNERA TION AND BENEFITS
2024
2023
Truslees, salaries
Trustees, social security
Trustees, pension contributions to money purchase schemes
7.672
239
211
8.122
Included in the remuneration paid to Ihe trustees in the prior year were amounts paid to Dr L Hartley for services
rendered in relation to the development and provision of distance learning courses.
Trustees, expenses
Within the expenses noted above are expenses paid to the following trustees in respect of dire¢1 charitable activily
costs i.e. travel expenses Leaching a( UK andlor International courses, und¢rtaken on behalf of Ihe charity in the
year:
2024
2023
Dr L Hartley
Dr S Jayaw2nl
Prof M KirkpatriLk
Dr A Parker
Dr A McLcllan
Dr M Griffiths
Dr D Lumsden
Dr S Mordekar
DrDRam
Dr S Amin
Dr M Prasad
Dr M Chitre
2.681
416
IU,719
483
45
427
195
139
164
649
14,153
564
4,425
636
658
709
1,623
720
149
23,637
15,918
During the year. in addition to the above. amounls tothlling £4,434 (2023 £5,264) related io executive tneeiing
expenses that were paid on behalf of all trusiees.
Page 50
continued..

Brliish Paediatrie Neurology Associatio
Iyotes to the Financial Statements- continued
for the Ye*r Ended 31 March 2024
ii.
STAFF COSTS
2024
2023
Wages and salaries
Social security cosis
Pension schemes
356,738
29,887
21,053
345,432
30,948
16,993
Total
407,678
393,373
Included within creditors as ai the reporting date is £nil (2023 £3.200) in relation Lo unpaid pension conlribulions.
The average monthly number of employees during the y&qr w&$ as follows..
2024
2023
Management
Support btaff
The number of employees receiving gross remuneralion, inclusive of Ihe value of benefits-in-kind, greater than
£60,000 per annum and lo whom retirement benefits are a¢¢ruing under defined contribution pension schemes were..
2024
2023
£60,(X)0 - £70,OtK)
Total employees
Total remuneration paid lo key management personnel during the financial year included wages and salaries
amounting lo £161,792 (2023 - £193,941) and contributions io defined contribution pension schemes of £10.055
(2023- £9,073).
Page51
continued..

Brltlsh Paediatric Neurology Association
Notes ¢0 the Flnanclal Statements . conUnued
for the Year Ended 31 March 2024
12.
TANGIBLE FIXED ASSETS
Fixtures
and
fittings
Plant and
machinery
Totals
COST
Al l April 2023
Additions
Disposals
32,696
18.610
5,947)
3.321
36,017
18,610
6,21L)
(2()41
At 31 March 2024
45,359
3,O.57
48,416
DEPRECIATION
At l April 2023
Charge for year
Eliminated on disposal
22,926
6,931
2,689
150
25,615
7,081
At 31 March 2024
24,566
2,607
27.173
NET BOOK VALUE
At 31 Ma￿h 2024
20,793
450
21.243
At 31 March 2023
632
13.
STOCKS
2024
2023
Stocks
9,023
11.061
14.
DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024
2023
Trade d¢btors
Prepayments and accrued income
21,660
43.543
32,977
7,074
65.203
40.051
Page 52
Continued...

British Paedlatrlc Neurology Association
Note5 to the Financiol Statements- continued
for th¢ Year Ended 31 March 2024
15.
CREDITORS: AMOUNTS FALLING DUE WJTHIN ONE YEAR
2024
2023
Trade creditors
Social security and other taxes
Other creditors
Defeffed income
Accrued expenses
59,830
I4.￿2
154
84,301
26.966
26,472
11.904
3,354
43,761
24,520
185.253
110.011
The deft￿cd inL()mc balance above includes income relating to traiuing courses amounting trj £84,171 (2023
£43,631) and membership subscriptions received in advance amounting to £130 (2023 - £130).
16.
LEASING AGREEMENTS
Minimum lease payments under non-cancellable operating leases fall due as follows..
2024
2023
Within one year
Between one and five years
16,534
3,578
11,628
20.112
11,628
During the ye&r the charity incurred expenditure under cancellable and non-cancellable operating lease agreements
relating lo office rental amounting to £47,567 {2023 - £49,638).
Page 53
continu¢d...

British Paedlatrlc Neurology Assoclatlon
Notes to the Flnanclal Statements . conthiued
for the Year Ended 31 March 2024
17.
MOVEMENT IN FUM)S
Net
movement
in funds
Transfers
between
funds
At
3113124
At 114123
Unrestrieted fun(Lq
General fund
Contin8¢n¢y furtd
Research training fellowship fund
Fetal neurology course development
International faculty education fund
Kenya fellowship travel fund
Fellow travel bursary fund
Dlslance learning development fund
PET updafr course development
PET hot topics course development
Impact & evaluation consultancy
Movement disorders course development
PET 213 international update
International face to face launch
Website upgrade
348,574
180,0(K)
179.648
10.730
10,195
15.462
(200,606)
70,000
163,430
250,(KX)
96,679
10.448
(82,969)
(282)
(10,195)
I,O(M)
7.125
67.825
25,143
17.600
50.(KiO
21,722
(7,125)
(12,680)
(18.418)
(7,858)
(1.000)
(1,119)
(9,823)
55.145
(6,725)
(9,742}
49.0(K)
{20,603)
9,823
60,000
ioo,(K)o
l(K).(
919,562
(118,687)
(15,173)
785,702
Restricted funds
THET grant fund
Colombia launch
Zambia launch
In¢ern￿lOnaI faculty education & fellow
travel bursary fund
149,261
(10,929)
11,470
149.261
13.076
(2,147)
11.470
17.3?11
13.076
149.802
178.051
TOTAL FUNDS
932,638
31,115
963.753
Page 54
continued...

British Pgedlatrie Neurology Assoeiation
Notes to the Financlal Ststements - continued
for the Yegr Ended 31 March 2024
17.
MOVEMENT IN FUNDS - eontinued
Net movement in funds, included in Ihe above are a5 follows:
Incoming
resources
Resources
expended
Movement
in funds
Unrestricted funds
General fund
Research training fellowship fund
Fetal neurology course development
Disiance learning development fund
PET update course developmeni
PET hot topics course development
Impact & evaluation consultancy
Movement disorders course development
PET 213 international update
956,￿3
1941,181)
(82.969)
(282)
(12.680)
(18,418)
(7,858)
(1,000)
(1,119)
15,462
(82,969)
(282)
(12,680)
(18,418)
(7,858)
(I,(MM))
(1,119)
956,643
(1,075,330)
(118,687)
Restricted funds
ILAE grant fund
THET grant fund
Colombia launch
Zambia launch
54,877
159,504
(3,204)
49,945
(54,877)
(10,2431
(7,725)
38,475)
149,261
{10,9291
11.470
261,122
(111,320
149.802
TOTAL FUNDS
1 ?17.765
11.186,650)
31.115
Page 55
nlinued...

Brltlsh Paedla¢rlc Neurology Assoclatlon
Notes to the Flnanclal Statements- continued
for the Year Ended 31 Marth 2024
17.
MOVEMENT IN FUNDS - continued
Comparatlves for movement in funds
Nel
movement
in funds
Transfers
between
funds
At
3113f23
At lJ4122
Unrestricted funds
GenCr￿ fund
Conlingency fund
Research training fellowship fund
Priority setting project
Fetal ncurology course development
International faculty education fund
Kenya fellowship travel fund
Fellow travel bursary fund
Distance learning development fund
PET update course development
PET hot topics course development
Impact & evaluation consultancy
Movement disorder8 course development
PETI Anternational update
271,694
180,000
153.604
9.739
12,130
5,6LK)
l.O(K)
6.325
76.7(X)
30.0(X)
12,6(X)
50,0(X)
99.288
(22,408)
348.574
180.(K)O
179.648
26,044
(2,206)
(1,400)
895
(7.533)
10,730
10.195
3,700
800
(8,875)
(4,857}
5.IX)O
7.125
67.825
25.143
17.6(X)
50,0(X)
21.722
5,222
(9.741)
16.500
9,741
809.392
110,170
919.562
Restrlcted funds
Colombia launch
13,076
13.076
TOTAL FUNDS
809,392
123,246
.3?,()38
Page 56
continued.

British Paedlatrlc Neurology Association
r4otes ¢0 the Financial Statements- continued
for the Year Ended 31 March 2024
17.
MOVEMENT IN FUNDS- continued
Comparative nel movement in funds, included in the above are as follows:
Incoming
resoiirces
Resources
expended
MoveTnenL
in funds
Unrestrieted funds
General fund
Research training fellowship fund
Priority setting project
Fctal neurology cour.ge devclopment
Internalional faculty cducation fund
rellow travel bursary fund
Distance learning dcvclopment fund
PET updalc Lourse development
PET hol topics course developmcnt
Movcmettt disorder.q coursc dcyelopmenl
PE'I'I inlcrnaiiunal update
891,632
109,013
1792,344)
(82,969)
(2.206)
(1,4(X))
99,288
26,044
(2,2￿)
(1,4(X))
895
8(K)
(8,875)
(4.857)
5,000
5,222
(9,741)
895
800
400
11,250
5,000
7,500
30,IM)I
(9.275)
(16,107)
(2,278)
(39.742)
1,056,491
(946.321)
110,170
Restrieted funds
ILAE grant fund
Colombia launch
58,791
39.124
(58,791)
(2C).n48)
11 (176
97.915
184.839)
13,1176
TOTAL FUNDS
1,154,4116
11.031.101))
113,246
Coi)lin
I'und
The contingency fiind is held io suppoi't the staffing cost of running the BPNA Secretariat for a period of
approximately Six months (2023 - six rnonths} should there be any contingency that might lead to a significant
rediiction in BPNA operational activities, this equates to £250,0(K) (2023 - £180,CK)o).
Dislancc Icai'nin
devLI()
mcllt liind
1.he dislancc learning dev¥lopmeni fund is a designated fund sel up by the trustees in order to preserve the
aniieipated level of funding incurred for distance learning course development in the foreseeable future. This
funding is provided from transfers from the general fund and includ¢s costs towards a Moodl¢ provider.
Felal Neuinlii.
Coiiise Develo
The Fetal Neurvlogy course developmenl fund is a de.qignated fund 5Ct up by the Tru8lees lo fund development of
course designed lo improve training for anyone involved in curing and coun.selling a family whose tetus ha8 a
neurological abnvtmality. This funding i% provided fmm transfers from thc general fund.
Page 57
Colllinued...

British Paediatrie Neurology Associution
Notes to the Flnanelgl Statements - continued
ror the Year Ended 31 March 2024
17.
MOVEMENT IN FUNDS - eonlinued
InlLI'li'ili()Ii'il Lt'd
ILAE
ranl fiind
Thc BPNA and ILAE share a comtnilmcnt to improving care for childrcn with epilepsy. In 2005, the BPNA
dcvclopcd Paediatric Epilepsy Training (PED courses lo Irain hcalthcare worker$ 10 bctlcr diagnose and treal
children with seizures. PETI 15 now attended by almo%t cvciy paediatrician in the UK and thc COLwses have alNu
been Idunched ovcr4cas, sctting a gold %tandard for cpilcpsy care ai'ound ihE world. Ouiside of the UK. Ihc
programme currenily runs in.. Bra7.il, Ghana. India. Kenya. Mydnmar, Ncw ZEaland. South AfriLa, Sudan, Tanzania
and Uganda.
PET a]igns With the ILAE'S Edu¢ation Council's aim lo lea¢h competency in the diagnosis and clinical management
of epilepsy. with a focus on non-5pecialists i.e. paedialricians. It forms part of the portfolio of ediicational aciivities
that the ILAE aims to develop. It also supports Goal 2 of Ihe LLAE'S Sti'ategy 2030.. Support health professionals
worldwide lo enhance their knowledge and skills in the prevention, diagnosis, Irealment and care of epilepsy.
The BPNA aiid the ILAE first signed a pai'lnership agreement in 2018, Committing to bLiild on the success of the
Paediairic Epilepsy Training courses developed by the BPNA.
The ILAE has agreed to ¢over 40% of staff cogis in tlie BPNA'S Inlernaiional EdLication leani 13 staff memberg)
from April 2022 10 March 2026. This equates to a total of $278,844 over that time.
Fellow%lii
Fiiiid
ThL Re&L￿¢h Training Fellowship funds iraii)ee clinicians to compleie a rese￿ch degree (eg PhD) in ihe field of
clinical neurology andlor neuroscience, including neurodisabiliiy and neurodevelopment. Fellowship applicaiils are
pre-docloral trainee clinicians who either alrcady liold a UK or Irish 4peLialist trdining post in Paediairic Neiirology
01 arc planning to apply for a SPCLidlis1 tsaining post in Paedi<itriL Neurology or Neurodisubilily aftcr completion of
their PhD. Both the pri)posed appliLcilion and fellowghip applicant must meet the BPNA chdl'itable aims.
Income to this fund is froTn men)bers' donalions and thc income from spotLsoi¢d 5yn]posia at the BPNA annual
conference.
Since 2015, Ihc BPNA has partnered with Action Medical Re.%carch to fund a joini Research Ti'aiDing Fellowship
award. Applicatinn.% for Ehis joint award arc considered in open ¢OTnpctition through Ihe Action Mcdical Research
peer review sy51cm.
Wehsile lJ
I'ade
Thc BPNA intends lo update their website. Thi.s fund was sei up by the Trustees to ¢over the initial cost of research and part
development of the website.
Inicmalion<il I'dce Eo 141¢¢ l.Aunch fund
Tliis is a dc5ignated fund set up by the Trustee5 to support fullire face to face international launches that may not cover all the
costs to adminisler a launch in a new couniry up Linlil March 2026. So far this fund has not needed io be ulilised
Page58
coniinued..,

British Paediatric Neurology Association
Notes lo the Financlal Statements . contlnued
for the Year Ended 31 March 2024
17.
MOVEMENT IN FUNDS - continued
InlcrnationLEI Paculi F.diicaiioii Fund
To enable low and middle income country (LMIC) BPNA course faculty lo benefit from BPNA educalion by
funding registration fees. The aim is to support faculty to pay (or courses that Ihey would otherwise be unable EO
afford. BPNA Education includes.. face-io-face courses and confei'ences held in the UK. wiriual courses or
conferences and enrolmenl on distance learning units. It does nol fund travel or accommodation.
Ken
,1 Travel P¥ll(Iw%hi
Fiind
In 2019. the BPNA and Kenyan Paedialric Association established a fellowship for UK pa¢diatric neurologists to go
to work in Kenya for a short period. The KPA will pay the UK clinician's salary. This fund is lo cover the cost of
their return travel expenses.
PETI Dcvel
PETI was lasi updated in January 2018. This money will fund the bringing iogeiher of an inlernalional
development team to update PETI course materials lo reflect feedback, updates in research and guidance.
PET 4w<ll'd Louf%L dLvcIo
To fund developmcnt OF a n¢w coiirse designed for Ihose who attended PET2 and 3 more than 3-years ago.
lil & Evci1111c tioii O(fiLCI'
The BPNA hab bccn running courses Since 2005. Thi.8 money has been aimed lo fund an Impacl and Evaluation
Officer to reporl on the full impacl of BPNA courses. Parl of that fund has been used lo pay for Consuliants from a
Universiiy io review impact & evaluation.
M()vc.mciii Disoi'dei'% Lniif%L develo
Iiienl
MOVED
MOVED is a 2-day course being developed by Consuliani Paedi&tri¢ Neurologists and Paediatricians in
Neurodisability. It will run as a siand alone course, but will develop themes from the Approaching Children's Tone
(ACT) course.
This course aims to cover a broad spectrum of movement disorders that are seen in children and will place emphasls
on description, diagnosis and initial management of these conditions.
Columbi2 Launch Fund
In partnership with the Univer51ty of Antioquia and ASCONI, the Colombian Child Neurology Sociely, BPNA
launched PETI in Colombia in August 2022. The Buisi Fund - University of Dundee, ILAE South America Region
and Jazz Pharma¢eulicals have contributed to the Columbia Launch Fund.
rant ILind
The BPNA were awarded a large Tropical Healih & Education Trust ITHET) grant. Using the eslablished
partnerships with the Paediatric Society of Ghana and East African Child Neurology Association in Kenya, the
BPNA a￿ delivering one-day PET Course in those countries. The aim is lo increase the nutnber of country
volunteer trainers, widen the geographical reach within those countries and carefully evaluate changes in practice
of the parlicipanls. The grant started in February 2023 and will end in February 2024.
Zambia Fund
The BPNA launched PETI in Zambia wilh delegates also coming from Zimbabwe. The Launch was supported by
BAND Foundation and the ILAE Africa Region.
Page 59
¢onlinued...

British Paedlatrlc Neurology Association
Notes to the Financial Statements . continued
for the Year Ended 31 March 2024
17.
MOVEMEN'f UND.S . continued
Transfers between funds
The transfers between designated funds and ihe general fund have been undertaken in ord¢r lo ensure a suitable
level of reserves has been designated as at ihe reporting date for Ihe purposes of the funds listed.
During the year, there was a transfer froJn the Colombia Launch restricted fund to the General fund of £2,147 (2023
£124 from General fund to Colombia Launch restri¢led fund).
18.
CONTINGENT LIABILITY
During the year to 31 March 2024, the chariiy has become aware that cei'tain areas of ils sponsotship income are
eligible for VAT. The charity has exceeded ilie V AT registration threshold, and as a result, is liable for V AT on this
income in the current and prior years. The final amoiint of the VAT liability is siill being considered. It is noi
possible ai ihis stagc to quantify the liability as ihe charity is yet lo confirm the levLI of iaxable income arising Imm
non-UK based customers or to lh¢ Lxtcnt to which the charity may bL rciTnburscd by cu.stomer.8. How¥vcr, thc fi'inal
V Al, liabilily is nut cxpecicd to exceed £112,0(X).
19.
RFLATED PARTY DISCLOSURES
Thcrc wcrc no related party tran8aclions for thc ycar cnded 31 March 2024 12023 - £1.973 of payments wer¥ nIt￿C
lo HMLH Con.8uliing i.td loi" thc provision of distance learniT)g Lourscs. of which Di. L Hartley was diitclor and also
a prcviou5 Iruslee of BPNAI. Dr L Hartl¢y slepped down as Iruslee on 16 January 2023.
ULTIMATE CONTROLLING PARTY
The trustees Consider there not io be one ultimate controlling party of the British Paediatric Neiirology Agsocialion
in the current or prior year.
P&ge 60